[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 453
1. Lim JH, Lee MH, Lee MJ, Kim CS, Lee JS, Choi SJ, Yi HG: Plasmablastic lymphoma in the anal canal. Cancer Res Treat; 2009 Sep;41(3):182-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma in the anal canal.
  • Plasmablastic lymphoma (PBL) of the oral cavity is an acquired immunodeficiency syndrome-related lymphoma.
  • Here, we describe a very rare case of PBL in the anal canal of a 40-year-old woman with human immunodeficiency virus infection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • [Cites] Orbit. 2008;27(3):227-9 [18569836.001]
  • [Cites] Histopathology. 2006 Apr;48(5):481-504 [16623775.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1633-41 [16327436.001]
  • [Cites] Cancer. 2005 Jun 25;105(3):139-44 [15803491.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Arch Pathol Lab Med. 2001 Feb;125(2):282-5 [11175653.001]
  • [Cites] Haematologica. 1998 Jan;83(1):87-9 [9542326.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Am J Hematol. 2004 Nov;77(3):291-5 [15495247.001]
  • [Cites] Am J Surg Pathol. 2004 Sep;28(9):1251-2 [15316328.001]
  • [Cites] Arch Pathol Lab Med. 2004 May;128(5):581-4 [15086296.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):41-6 [14707862.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • (PMID = 19809569.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2757665
  • [Keywords] NOTNLM ; Epstein-Bar virus / HIV / Plasmablastic lymphoma
  •  go-up   go-down


2. Lin O, Gerhard R, Zerbini MC, Teruya-Feldstein J: Cytologic features of plasmablastic lymphoma. Cancer; 2005 Jun 25;105(3):139-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of plasmablastic lymphoma.
  • This lymphoma has a heterogeneous morphologic presentation but distinct phenotype.
  • RESULTS: Specimens evaluated were two head and neck fine needle aspiration specimens, one anal smear, and one cerebrospinal fluid specimen.
  • CONCLUSION: PBL is a variant of large cell lymphoma with heterogeneous cytologic findings but distinct immunophenotype.
  • [MeSH-major] Cytodiagnosis / methods. Lymphoma, Large-Cell, Immunoblastic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803491.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Piccaluga PP, Agostinelli C, Gazzola A, Mannu C, Bacci F, Sabattini E, Pileri SA: Prognostic markers in peripheral T-cell lymphoma. Curr Hematol Malig Rep; 2010 Oct;5(4):222-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic markers in peripheral T-cell lymphoma.
  • However, it is not so satisfactory for the two commonest PTCLs, PTCL not otherwise specified (PTCL/NOS) and angioimmunoblastic T-cell lymphoma (AITL), for which novel scores, possibly based on the biologic features of the tumors, have been explored.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2009 Jul;94(7):1036-7 [19508975.001]
  • [Cites] Br J Haematol. 2010 Feb;148(3):402-12 [19863542.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Blood. 2010 Feb 11;115(6):1226-37 [19965620.001]
  • [Cites] J Clin Oncol. 2010 Mar 20;28(9):1583-90 [20159827.001]
  • [Cites] N Engl J Med. 2010 Apr 15;362(15):1417-29 [20393178.001]
  • [Cites] Ann Oncol. 2010 May;21(5):1032-40 [19850638.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):182-90 [12182990.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2213-9 [12750155.001]
  • [Cites] Blood. 2004 Jan 1;103(1):216-21 [12933580.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1837-48 [15111330.001]
  • [Cites] Blood. 2004 Jul 1;104(1):243-9 [15031209.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):174-85 [15211477.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):289-303 [15233906.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4971-82 [15297397.001]
  • [Cites] Mod Pathol. 2004 Sep;17(9):1097-107 [15195107.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Int J Surg Pathol. 2004 Oct;12(4):375-87 [15494863.001]
  • [Cites] Histopathology. 1993 Apr;22(4):303-10 [8514273.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):909-16 [8101471.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):337-44 [8908304.001]
  • [Cites] Histopathology. 2001 Mar;38(3):250-70 [11260307.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Br J Haematol. 1997 Jun;97(4):821-9 [9217183.001]
  • [Cites] Cell Prolif. 1997 Jan;30(1):37-47 [9332493.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):973-8 [9402170.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Anat Pathol. 1998;3:77-145 [10389582.001]
  • [Cites] Hum Pathol. 1999 Jul;30(7):849-55 [10414505.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Hematology. 2005 Jun;10(3):237-45 [16019472.001]
  • [Cites] Haematologica. 2005 Aug;90(8):1063-9 [16079105.001]
  • [Cites] Br J Haematol. 2005 Oct;131(1):29-38 [16173960.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):612-8 [16380410.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4500-7 [16484591.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4163-9 [16902151.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Haematologica. 2007 Apr;92(4):566-7 [17488672.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Mar;15(1):38-44 [17536305.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3250-4 [17545530.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3345-51 [17634410.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] J Clin Pathol. 2008 Nov;61(11):1160-7 [18755717.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1071-4 [18955564.001]
  • [Cites] Histopathology. 2009 Mar;54(4):478-85 [19309400.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):715-21 [19150954.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3931-7 [19029440.001]
  • [Cites] Blood. 2009 Apr 23;113(17):4016-26 [19131553.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):583-92 [9261528.001]
  • [ErratumIn] Curr Hematol Malig Rep. 2010 Oct;5(4):239
  • (PMID = 20690003.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.1.- / Lactate Dehydrogenases
  • [Other-IDs] NLM/ PMC2948168
  •  go-up   go-down


Advertisement
4. Freudenberg S, Palma P, Grobholz R, Ngendahayo L, Post S: HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case. Dis Colon Rectum; 2005 Aug;48(8):1656-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-related and Epstein-Barr virus-associated anal Burkitt's lymphoma: report of a case.
  • PURPOSE: This article describes and discusses primary Burkitt's lymphoma of the anus which is an extremely rare site of origin.
  • METHODS AND RESULTS: A 38-year-old HIV+ Rwandan farmer had an 8-cm x 13-cm anal tumor.
  • Histopathology and immunohistology provided evidence of an Epstein-Barr virus-associated Burkitt's lymphoma.
  • CONCLUSIONS: Because of the AIDS epidemic and the increase of anal malignant pathologies, anal Burkitt's lymphoma may appear more frequently.
  • [MeSH-major] Anus Neoplasms / diagnosis. Burkitt Lymphoma / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16034658.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Chatelain D, Mokrani N, Fléjou JF: [Anal and anal margin tumors]. Ann Pathol; 2007 Dec;27(6):459-75
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anal and anal margin tumors].
  • Tumors of the anal canal and anal margin are rare.
  • [MeSH-major] Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Endocrine Gland Neoplasms / epidemiology. Endocrine Gland Neoplasms / pathology. France / epidemiology. Humans. Incidence. Leiomyosarcoma / pathology. Lymphoma / pathology. Melanoma / epidemiology. Melanoma / pathology. Papilloma / pathology. Sarcoma, Kaposi / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18554556.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 110
  •  go-up   go-down


6. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LA, Fraumeni JF Jr: Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol; 2010 Nov 20;28(33):4935-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.
  • PURPOSE: Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype.
  • PATIENTS AND METHODS: We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006.
  • RESULTS: Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001).
  • Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90).
  • CONCLUSION: Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk.
  • Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):925-33 [15824165.001]
  • [Cites] Am J Epidemiol. 2010 Feb 1;171(3):267-76 [20047977.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):159-66 [15970927.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2402-6 [16214923.001]
  • [Cites] N Engl J Med. 2005 Nov 17;353(20):2135-47 [16291983.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):419-20 [16125820.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1568-74 [16520465.001]
  • [Cites] Cancer. 2006 Jul 1;107(1):108-15 [16708354.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1481-8 [17043014.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2314-20 [17107903.001]
  • [Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1099-102 [17131330.001]
  • [Cites] Cancer Causes Control. 2007 Mar;18(2):135-42 [17235495.001]
  • [Cites] Int J Cancer. 2007 Jul 1;121(1):151-6 [17351903.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4617-26 [17311989.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] Cancer Causes Control. 2008 Feb;19(1):43-50 [17906957.001]
  • [Cites] Haematologica. 2008 Mar;93(3):398-404 [18268277.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Apr;6(4):451-8 [18387498.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4029-38 [18263783.001]
  • [Cites] J Clin Oncol. 2008 Apr 10;26(11):1850-7 [18347006.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Apr;8(4):605-15 [18402527.001]
  • [Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]
  • [Cites] Expert Opin Pharmacother. 2008 Jun;9(9):1481-94 [18518779.001]
  • [Cites] Hematol Oncol Clin North Am. 2008 Oct;22(5):941-52, ix [18954744.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Jan 29;113(5):1175-83 [18971419.001]
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2454-60 [10561309.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):874-80 [11241258.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1610-8 [11250989.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [11830608.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):10-24 [11842384.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3878-84 [12228208.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):74-8 [12556962.001]
  • [Cites] Med Oncol. 2003;20(3):211-20 [14514970.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):383-9 [14746857.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1222-8 [14576060.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] J Acquir Immune Defic Syndr. 2004 Aug 15;36(5):1083-91 [15247562.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] J Natl Cancer Inst. 1995 Apr 5;87(7):524-30 [7707439.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):565-71 [8636772.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):216-28 [15578683.001]
  • [Cites] N Engl J Med. 2009 Feb 12;360(7):659-67 [19213679.001]
  • [Cites] J Natl Cancer Inst. 2009 Feb 18;101(4):248-55 [19211444.001]
  • [Cites] J Clin Oncol. 2009 Feb 20;27(6):904-10 [19114699.001]
  • [Cites] Nat Genet. 2009 Aug;41(8):873-5 [19620980.001]
  • [Cites] J Natl Cancer Inst. 2009 Aug 19;101(16):1120-30 [19648510.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4573-5 [15741224.001]
  • (PMID = 20940199.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3020697
  •  go-up   go-down


7. Winton Ed, Heriot AG, Ng M, Hicks RJ, Hogg A, Milner A, Leong T, Fay M, MacKay J, Drummond E, Ngan SY: The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer. Br J Cancer; 2009 Mar 10;100(5):693-700
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of 18-fluorodeoxyglucose positron emission tomography on the staging, management and outcome of anal cancer.
  • Accurate inguinal and pelvic nodal staging in anal cancer is important for the prognosis and planning of radiation fields.
  • We aimed to determine the effect of FDG-PET on the nodal staging, radiotherapy planning and prognostication of patients with primary anal cancer.
  • Sixty-one consecutive patients with anal cancer who were referred to a tertiary centre between August 1997 and November 2005 were staged with conventional imaging (CIm) (including computed tomography (CT), magnetic resonance imaging, endoscopic ultrasound and chest X-ray) and by FDG-PET.
  • FDG-PET shows increased sensitivity over CIm for staging nodal disease in anal cancer and changes treatment intent or radiotherapy prescription in a significant proportion of patients.
  • [MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Fluorodeoxyglucose F18. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2001 Mar;218(3):776-82 [11230656.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):168-71 [2703175.001]
  • [Cites] Cancer. 2001 Aug 15;92(4):886-95 [11550162.001]
  • [Cites] Radiology. 1999 Nov;213(2):530-6 [10551237.001]
  • [Cites] N Engl J Med. 2000 Mar 16;342(11):792-800 [10717015.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):272-8 [11703321.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Apr;29(4):506-15 [11914889.001]
  • [Cites] Gynecol Oncol. 2002 Apr;85(1):179-84 [11925141.001]
  • [Cites] Clin Lymphoma. 2003 Jun;4(1):43-9 [12837154.001]
  • [Cites] Semin Surg Oncol. 2003;21(3):149-55 [14508847.001]
  • [Cites] Dis Colon Rectum. 2004 Apr;47(4):451-8 [14978612.001]
  • [Cites] Dis Colon Rectum. 1974 May-Jun;17(3):354-6 [4830803.001]
  • [Cites] AJR Am J Roentgenol. 1983 Jan;140(1):95-9 [6600330.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1285-93 [6692319.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2527-39 [8823332.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2040-9 [9164216.001]
  • [Cites] Cancer. 1998 May 1;82(9):1664-71 [9576286.001]
  • [Cites] J Surg Oncol. 1999 Feb;70(2):71-7 [10084647.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1686-93 [10223561.001]
  • [Cites] J Nucl Med. 1999 Aug;40(8):1257-63 [10450675.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):41-5 [10458216.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):479-85 [15890590.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1301-15 [15793642.001]
  • [Cites] Mol Imaging Biol. 2005 Jul-Aug;7(4):309-13 [16028002.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):247-52 [16289647.001]
  • [Cites] Radiother Oncol. 2006 Mar;78(3):254-61 [16545881.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):720-5 [16626889.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jul;33(7):770-8 [16550384.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):419-24 [17919842.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • (PMID = 19259091.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC2653751
  •  go-up   go-down


8. Steidl C, Lee T, Shah SP, Farinha P, Han G, Nayar T, Delaney A, Jones SJ, Iqbal J, Weisenburger DD, Bast MA, Rosenwald A, Muller-Hermelink HK, Rimsza LM, Campo E, Delabie J, Braziel RM, Cook JR, Tubbs RR, Jaffe ES, Lenz G, Connors JM, Staudt LM, Chan WC, Gascoyne RD: Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. N Engl J Med; 2010 Mar 11;362(10):875-85
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.
  • BACKGROUND: Despite advances in treatments for Hodgkin's lymphoma, about 20% of patients still die from progressive disease.
  • METHODS: Using gene-expression profiling, we analyzed 130 frozen samples obtained from patients with classic Hodgkin's lymphoma during diagnostic lymph-node biopsy to determine which cellular signatures were correlated with treatment outcome.
  • RESULTS: Gene-expression profiling identified a gene signature of tumor-associated macrophages that was significantly associated with primary treatment failure (P=0.02).
  • CONCLUSIONS: An increased number of tumor-associated macrophages was strongly associated with shortened survival in patients with classic Hodgkin's lymphoma and provides a new biomarker for risk stratification.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • SciCrunch. ArrayExpress: Data: Microarray .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Massachusetts Medical Society
  • [Cites] Ann Oncol. 2006 Jan;17(1):110-6 [16291580.001]
  • [Cites] Immunol Rev. 2006 Apr;210:67-85 [16623765.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2431-42 [16760443.001]
  • [Cites] Blood. 2006 Jul 15;108(2):662-8 [16551964.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(1):41-7 [17115062.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3101-8 [17536082.001]
  • [Cites] J Surg Res. 2007 Sep;142(1):119-28 [17597158.001]
  • [Cites] Eur J Haematol. 2007 Nov;79(5):455-61 [17908180.001]
  • [Cites] Am J Clin Pathol. 2007 Dec;128(6):958-65 [18024321.001]
  • [Cites] Haematologica. 2008 Feb;93(2):193-200 [18223287.001]
  • [Cites] Clin Cancer Res. 2008 Mar 15;14(6):1759-66 [18347177.001]
  • [Cites] N Engl J Med. 2008 Nov 27;359(22):2313-23 [19038878.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Blood. 2009 Mar 19;113(12):2765-3775 [19096012.001]
  • [Cites] Blood. 2009 Jun 4;113(23):5920-6 [19188663.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3095-102 [12082542.001]
  • [Cites] Trends Immunol. 2002 Nov;23(11):549-55 [12401408.001]
  • [Cites] Cancer. 2003 Jul 15;98(2):310-4 [12872350.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:225-47 [14633784.001]
  • [Cites] J Nutr. 2004 Apr;134(4):762-70 [15051823.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] N Engl J Med. 1992 Nov 19;327(21):1478-84 [1383821.001]
  • [Cites] Ann Oncol. 1995 Nov;6(9):895-9 [8624292.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]
  • [Cites] Blood. 2005 May 15;105(10):3979-86 [15677569.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3773-9 [15809450.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2005 Jun;27(6):957-68 [15943426.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cell Immunol. 2005 May;235(1):21-8 [16165118.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1581-91 [16236613.001]
  • [CommentIn] N Engl J Med. 2010 Mar 11;362(10):942-3 [20220189.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136 [20527079.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135-6; author reply 2136 [20527059.001]
  • [CommentIn] N Engl J Med. 2010 Jun 3;362(22):2135; author reply 2136 [20519687.001]
  • (PMID = 20220182.001).
  • [ISSN] 1533-4406
  • [Journal-full-title] The New England journal of medicine
  • [ISO-abbreviation] N. Engl. J. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114778; Canada / Canadian Institutes of Health Research / / 178536; United States / NCI NIH HHS / CA / U01 CA114778-05; United States / Intramural NIH HHS / / ; United States / NCI NIH HHS / CA / U01-CA114778-01; United States / NCI NIH HHS / CA / CA114778-05; United States / NCI NIH HHS / CA / U01-CA 114778
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Biomarkers, Tumor; 0 / CD68 antigen, human; 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ NIHMS194035; NLM/ PMC2897174
  •  go-up   go-down


9. Sissolak G, Sissolak D, Jacobs P: Human immunodeficiency and Hodgkin lymphoma. Transfus Apher Sci; 2010 Apr;42(2):131-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency and Hodgkin lymphoma.
  • Presentation of Hodgkin lymphoma (HL) is distinctive in the infected individual being more advanced, accompanied by B symptoms and the presence of extranodal disease particularly lymphadenopathy of the head and neck.
  • Current consensus holds this particular lymphoma as still among the non-AIDS defining cancers being lung, stomach, liver or anal despite these having recently gained more attention as several of these neoplasms may be occurring more commonly in the era of cART.
  • Based on the precedent in which Kaposi sarcoma and the non-Hodgkin lymphomas distinctively alter the course of this retroviral infection in a way indistinguishable from concurrent Hodgkin lymphoma we propose that this entity be similarly regarded and the hypothesis tested in large randomised prospective study.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010. Published by Elsevier Ltd.
  • (PMID = 20138008.001).
  • [ISSN] 1473-0502
  • [Journal-full-title] Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • [ISO-abbreviation] Transfus. Apher. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 122
  •  go-up   go-down


10. Siddique K, Bhandari S, Harinath G: Epstein-Barr virus (EBV) positive anal B cell lymphoma: a case report and review of literature. Ann R Coll Surg Engl; 2010 Apr;92(3):W7-9
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus (EBV) positive anal B cell lymphoma: a case report and review of literature.
  • This case report is on a very rare case of giant anal canal ulcer with rectal prolapse causing total faecal incontinence.
  • An elderly patient in her eighties presented to the emergency department with complaints of a mass protruding thorough anus along with fresh rectal bleeding.
  • Examination revealed a large ulcer measuring 6 cm x 8 cm involving the entire anal canal with rectal prolapse.
  • Here, we discuss the management of this patient with a rare cause of giant anal canal ulceration.
  • [MeSH-major] Anus Neoplasms / virology. Epstein-Barr Virus Infections / complications. Lymphoma, Large B-Cell, Diffuse / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20412659.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 9
  •  go-up   go-down


11. García Ortiz LM, Jaume Anselmi F, Ramírez Rivera J, Casiano Quiles W, Márquez Santiago R: Non-Hodgkin's lymphoma presenting as ulcerative colitis. Bol Asoc Med P R; 2006 Apr-Jun;98(2):140-3
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma presenting as ulcerative colitis.
  • We report a high grade small B-cell (Burkitt's like) Non-Hodgkin's lymphoma that initially was considered and treated as ulcerative colitis without improvement or resolution of symptoms for nine months.
  • Acute lesions of ulcerative colitis begin at the anal verge and involve only the mucosa and submucosa.
  • [MeSH-major] Colitis, Ulcerative / etiology. Lymphoma, Non-Hodgkin / complications

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19606804.001).
  • [ISSN] 0004-4849
  • [Journal-full-title] Boletín de la Asociación Médica de Puerto Rico
  • [ISO-abbreviation] Bol Asoc Med P R
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Puerto Rico
  •  go-up   go-down


12. de Oliveira KB, Oda JM, Voltarelli JC, Nasser TF, Ono MA, Fujita TC, Matsuo T, Watanabe MA: CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. J Clin Lab Anal; 2009;23(6):387-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma.
  • The single-nucleotide polymorphism (SNP) rs1801157 (previously known as CXCL12-A/ stromal cell-derived factor-1 (SDF1)-3'A) in CXCL12/SDF1 gene was assessed in breast cancer, Hodgkin's lymphoma (HL), and non-Hodgkin's lymphoma (NHL), since the chemokine CXCL12, previously known as SDF1, and its receptor CXCR4 regulate leukocyte trafficking and many essential biological processes, including tumor growth, angiogenesis, and metastasis of different types of tumors.
  • [MeSH-major] Breast Neoplasms / genetics. Chemokine CXCL12 / genetics. Hodgkin Disease / genetics. Lymphoma, Non-Hodgkin / genetics. Polymorphism, Single Nucleotide / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927352.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chemokine CXCL12
  •  go-up   go-down


13. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • Among the 299 cases (54.2%) of NAD malignomas were 213 solid tumors including 71 anal carcinomas (= 33.5% of all NAD malignancies) and 85 hemoblastoses including 29 Hodgkin lymphomas (= 9.6% of all NAD malignancies).
  • Interestingly, only 1 of 8 primary cerebral lymphomas has been reported after 2001.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • Anal carcinomas and Hodgkin's lymphomas in particular were markedly more prevalent in our HIV-positive cohort compared to published reports of the general population.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Balachandra B, Marcus V, Jass JR: Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist. Histopathology; 2007 Jan;50(1):163-74
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated tumours of the anal canal: a diagnostic strategy for the surgical pathologist.
  • Poorly differentiated malignancies affecting the anal canal are uncommon but pose diagnostic difficulties because of the wide range of normal cell types that may occur within a limited anatomical region.
  • The range of lesions that may present as poorly differentiated tumours includes squamous cell carcinoma, adenocarcinoma, small and large cell neuroendocrine carcinoma, neuroendocrine carcinoma expressing epithelial cytokeratins and other patterns of mixed differentiation, undifferentiated carcinoma, malignant melanoma, lymphoma and secondary tumours.
  • [MeSH-major] Anal Canal / pathology. Anus Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Female. Humans. Lymphoma / pathology. Male. Melanoma / pathology. Middle Aged. Pathology, Surgical / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204029.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 72
  •  go-up   go-down


15. Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E: Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol; 2006 Aug;4(8):1030-4
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease.
  • The risk of lymphoma in inflammatory bowel disease (IBD) has raised concerns regarding the lymphogenic potential of immunomodulatory therapy.
  • The link between immunosuppressive therapy and lymphoma risk is well established in patients with solid organ transplantations.
  • In this report, we describe a case of EBV-positive non-Hodgkin's lymphoma arising in the ileal pouch of a patient with ulcerative colitis.
  • [MeSH-major] Anastomosis, Surgical. Colitis, Ulcerative / drug therapy. Colonic Pouches. Ileum / surgery. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2007 Apr;5(4):521; author reply 521-2 [17445756.001]
  • [CommentOn] Clin Gastroenterol Hepatol. 2006 Aug;4(8):976-8 [16880119.001]
  • (PMID = 16854631.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone
  •  go-up   go-down


16. Belkacem-Boussaid K, Pennell M, Lozanski G, Shana'ah A, Gurcan M: Computer-aided classification of centroblast cells in follicular lymphoma. Anal Quant Cytol Histol; 2010 Oct;32(5):254-60
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-aided classification of centroblast cells in follicular lymphoma.
  • OBJECTIVE: To distinguish centroblast cells from non-centroblast cells using a novel automated method in follicular lymphoma cases and measure its performance on cases obtained by a consensus of six pathologists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Phys. 2002 Nov;29(11):2552-8 [12462722.001]
  • [Cites] J Clin Pathol. 1988 Aug;41(8):866-70 [3170773.001]
  • [Cites] N Engl J Med. 2007 Apr 5;356(14):1399-409 [17409321.001]
  • [Cites] Anal Quant Cytol Histol. 2008 Dec;30(6):323-35 [19160697.001]
  • (PMID = 21509147.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA134451; United States / NCI NIH HHS / CA / R01 CA134451-01A1; United States / NCI NIH HHS / CA / R01CA134451
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS252602; NLM/ PMC3078581
  • [Keywords] NOTNLM ; CB cell / Follicular lymphoma / classification / color texture features / geometrical features / non-CB cell / principal component analysis / sensitivity / specificity / spectral domain
  •  go-up   go-down


17. Matsumoto T, Nakamura S, Esaki M, Yada S, Moriyama T, Yanai S, Hirahashi M, Yao T, Iida M: Double-balloon endoscopy depicts diminutive small bowel lesions in gastrointestinal lymphoma. Dig Dis Sci; 2010 Jan;55(1):158-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double-balloon endoscopy depicts diminutive small bowel lesions in gastrointestinal lymphoma.
  • The aim was to determine the prevalence of small bowel involvement in patients with gastrointestinal (GI) lymphoma by double-balloon endoscopy (DBE).
  • We examined 29 patients with primary GI lymphoma by oral and anal DBEs.
  • The prevalence of the lesions was not different between patients with primary small bowel lymphoma and those with primary extra-small bowel lymphoma (50% versus 47%, P = 0.6).
  • The lesions were more frequently found in T-cell lymphoma (100%) and follicular lymphoma (77%) than in the other types of lymphoma (15%) (P < 0.05).
  • Diminutive small intestinal lesions occur in patients with GI lymphoma, especially in those with follicular lymphoma and T-cell lymphoma.
  • [MeSH-major] Endoscopy, Gastrointestinal. Gastrointestinal Neoplasms / diagnosis. Intestine, Small / pathology. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19241169.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Peralta EA: Rare anorectal neoplasms: gastrointestinal stromal tumor, carcinoid, and lymphoma. Clin Colon Rectal Surg; 2009 May;22(2):107-14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare anorectal neoplasms: gastrointestinal stromal tumor, carcinoid, and lymphoma.
  • Several uncommon tumors occur in the anal canal such as gastrointestinal stromal tumors, carcinoids, and lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):946-54 [10435565.001]
  • [Cites] Cancer. 1971 Jul;28(1):175-80 [5110628.001]
  • [Cites] World J Surg. 2000 Apr;24(4):437-43 [10706916.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):950-6 [11598163.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1607-12 [12760929.001]
  • [Cites] Am J Surg. 1964 Jun;107:844-9 [14169012.001]
  • [Cites] Ann Surg Oncol. 2004 May;11(5):465-75 [15123459.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1922-9 [15622586.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1587-95 [15742328.001]
  • [Cites] Dis Colon Rectum. 1992 Apr;35(4):328-31 [1582353.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):762-7 [1612575.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] Dis Colon Rectum. 1992 Aug;35(8):717-25 [1643994.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):609-15 [16552495.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1466-78 [17090188.001]
  • [Cites] World J Surg Oncol. 2007;5:20 [17306018.001]
  • [Cites] Surg Today. 2007;37(6):455-9 [17522761.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Jul;5 Suppl 2:S1-29; quiz S30 [17624289.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):608-15 [18076015.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):350-9 [18286477.001]
  • [Cites] J Surg Oncol. 2009 Jan 1;99(1):42-7 [18942073.001]
  • [Cites] Br J Surg. 1984 Aug;71(8):597-9 [6743978.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1294-8 [9083149.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):997-1006 [9298875.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] J Surg Oncol. 2006 Mar 15;93(4):304-11 [16496358.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):396-404 [17094024.001]
  • [Cites] Indian J Gastroenterol. 2007 Jan-Feb;26(1):33-5 [17401234.001]
  • [Cites] Nat Clin Pract Oncol. 2008 May;5(5):240-1 [18349856.001]
  • [Cites] Arch Surg. 2008 May;143(5):471-5 [18490556.001]
  • [Cites] Surgery. 2008 Sep;144(3):460-6 [18707046.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2194-201 [18708414.001]
  • [Cites] Z Gastroenterol. 2008 Aug;46(8):760-5 [18759198.001]
  • [Cites] Oncologist. 2008 Dec;13(12):1255-69 [19091780.001]
  • [Cites] Dis Colon Rectum. 1997 Sep;40(9):1101-18 [9293943.001]
  • [Cites] Histopathology. 1988 Mar;12(3):235-52 [3366441.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • (PMID = 20436835.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780247
  • [Keywords] NOTNLM ; Gastrointestinal stromal tumors / carcinoid / lymphoma
  •  go-up   go-down


19. Orlov NV, Chen WW, Eckley DM, Macura TJ, Shamir L, Jaffe ES, Goldberg IG: Automatic classification of lymphoma images with transform-based global features. IEEE Trans Inf Technol Biomed; 2010 Jul;14(4):1003-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Automatic classification of lymphoma images with transform-based global features.
  • We propose a report on automatic classification of three common types of malignant lymphoma: chronic lymphocytic leukemia, follicular lymphoma, and mantle cell lymphoma.
  • The goal was to find patterns indicative of lymphoma malignancies and allowing classifying these malignancies by type.
  • [MeSH-major] Automation. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1999 Dec;10(12):1419-32 [10643532.001]
  • [Cites] Bioinformatics. 2009 Dec 1;25(23):3060-3 [19808878.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2000 Dec;4(4):265-73 [11206811.001]
  • [Cites] Anal Quant Cytol Histol. 2001 Aug;23(4):291-9 [11531144.001]
  • [Cites] Anal Cell Pathol. 2003;25(1):1-36 [12590175.001]
  • [Cites] IEEE Trans Med Imaging. 2004 Jan;23(1):73-84 [14719689.001]
  • [Cites] Ann N Y Acad Sci. 2004 May;1020:124-31 [15208189.001]
  • [Cites] Adv Anat Pathol. 2005 Jan;12(1):27-34 [15614162.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2005 Aug;27(8):1226-38 [16119262.001]
  • [Cites] Artif Intell Med. 2006 Jan;36(1):71-84 [16412950.001]
  • [Cites] Oncology (Williston Park). 2006 Mar;20(3):231-9; discussion 242, 244, 249 [16629256.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2007 Mar;11(2):203-12 [17390990.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2007 May;11(3):338-47 [17521084.001]
  • [Cites] IEEE Trans Inf Technol Biomed. 2007 May;11(3):353-9 [17521086.001]
  • [Cites] Hum Pathol. 2007 Aug;38(8):1212-25 [17490722.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] BMC Cancer. 2007;7:164 [17718897.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Dec;46(12):1090-7 [17823928.001]
  • [Cites] IEEE Trans Med Imaging. 2007 Oct;26(10):1366-78 [17948727.001]
  • [Cites] Chest. 2008 Jan;133(1):137-42 [17951620.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2008 Sep;30(9):1534-46 [18617713.001]
  • [Cites] PLoS One. 2008;3(7):e2821 [18665238.001]
  • [Cites] Med Biol Eng Comput. 2008 Sep;46(9):943-7 [18668273.001]
  • [Cites] IEEE Trans Biomed Eng. 2009 Feb;56(2):407-15 [19342330.001]
  • [Cites] Osteoarthritis Cartilage. 2009 Oct;17(10):1307-12 [19426848.001]
  • [Cites] Comput Methods Programs Biomed. 2009 Dec;96(3):182-92 [19487043.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1161-6 [11106071.001]
  • (PMID = 20659835.001).
  • [ISSN] 1558-0032
  • [Journal-full-title] IEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society
  • [ISO-abbreviation] IEEE Trans Inf Technol Biomed
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 AG000685-01; United States / Intramural NIH HHS / / ZIC AG000685-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS204114; NLM/ PMC2911652
  •  go-up   go-down


20. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M: Pathway analysis of primary central nervous system lymphoma. Blood; 2008 Mar 15;111(6):3200-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathway analysis of primary central nervous system lymphoma.
  • Primary central nervous system (CNS) lymphoma (PCNSL) is a diffuse large B-cell lymphoma (DLBCL) confined to the CNS.

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2000 Dec;47(6):1400-9 [11126911.001]
  • [Cites] Bioinformatics. 2001 Jun;17(6):520-5 [11395428.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1731-5 [11721059.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 28;1552(2):61-85 [11825687.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Bioinformatics. 2002 Aug;18(8):1054-63 [12176828.001]
  • [Cites] J Immunol. 2002 Sep 1;169(5):2507-15 [12193720.001]
  • [Cites] Blood. 2003 Feb 1;101(3):815-21 [12393412.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1063-9 [12631608.001]
  • [Cites] Brain. 2003 May;126(Pt 5):1058-67 [12690046.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):184-90 [14734468.001]
  • [Cites] Hum Pathol. 2004 Jan;35(1):122-8 [14745734.001]
  • [Cites] Mol Carcinog. 2004 May;40(1):47-61 [15108329.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3029-34 [15131039.001]
  • [Cites] Anal Biochem. 2004 Aug 15;331(2):243-54 [15265729.001]
  • [Cites] Lancet. 1983 Mar 5;1(8323):498-501 [6131211.001]
  • [Cites] J Clin Invest. 1988 Jul;82(1):331-9 [2839550.001]
  • [Cites] Acta Neuropathol. 1993;86(4):360-4 [8256586.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4313-20 [8044778.001]
  • [Cites] J Neurooncol. 1995;24(1):33-6 [8523072.001]
  • [Cites] Int J Cancer. 1996 Nov 4;68(3):325-32 [8903474.001]
  • [Cites] Cell. 1997 Dec 26;91(7):869-72 [9428509.001]
  • [Cites] Blood. 1998 Aug 1;92(3):1011-9 [9680371.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4247-50 [15557427.001]
  • [Cites] Curr Opin Oncol. 2005 Mar;17(2):167-71 [15725923.001]
  • [Cites] Laryngoscope. 2005 Jul;115(7):1239-42 [15995513.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):640-8 [16056259.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 20;102(38):13544-9 [16174746.001]
  • [Cites] Blood. 2006 Jan 1;107(1):190-6 [16150948.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2006;:311-6 [17124077.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Dec;17(6):463-74 [17113338.001]
  • [Cites] Oncogene. 2006 Dec 4;25(57):7469-81 [17143291.001]
  • [Cites] Expert Opin Ther Targets. 2007 Feb;11(2):219-34 [17227236.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Feb;292(2):C919-26 [17005603.001]
  • [Cites] World J Surg Oncol. 2007;5:17 [17286869.001]
  • [Cites] Neurobiol Aging. 2008 Dec;29(12):1874-93 [17560690.001]
  • [CommentIn] Blood. 2009 Jan 1;113(1):266-7; author reply 267-8 [19122120.001]
  • (PMID = 18184868.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / P30 CA015083; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / P30 CA15083; United States / NCI NIH HHS / CA / P50 CA97274
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2265457
  •  go-up   go-down


21. Kocjan G: Best Practice No 185. Cytological and molecular diagnosis of lymphoma. J Clin Pathol; 2005 Jun;58(6):561-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Best Practice No 185. Cytological and molecular diagnosis of lymphoma.
  • With the advances in molecular pathology, the cell as a morphological and functional unit has become essential in the diagnosis of lymphoma.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):85-94 [10564590.001]
  • [Cites] Arch Pathol Lab Med. 1999 Dec;123(12):1189-207 [10583924.001]
  • [Cites] Cytopathology. 1999 Oct;10(5):291-7 [10588346.001]
  • [Cites] Cancer. 1999 Dec 25;87(6):325-45 [10603186.001]
  • [Cites] Am J Clin Pathol. 2000 May;113(5):688-99 [10800402.001]
  • [Cites] Nature. 2000 Nov 9;408(6809):216-21 [11089977.001]
  • [Cites] N Engl J Med. 2004 Aug 26;351(9):856-7 [15329421.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1781-7 [1356511.001]
  • [Cites] Blood. 1992 Nov 15;80(10):2594-9 [1384792.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2289-95 [8400281.001]
  • [Cites] Oncogene. 1993 Dec;8(12):3447-57 [8247550.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Am J Pathol. 1994 Jun;144(6):1312-9 [8203469.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Acta Cytol. 1995 Mar-Apr;39(2):180-6 [7887065.001]
  • [Cites] Diagn Mol Pathol. 1995 Mar;4(1):25-31 [7735552.001]
  • [Cites] Blood. 1996 Dec 1;88(11):4110-7 [8943844.001]
  • [Cites] Cytopathology. 1997 Apr;8(2):114-21 [9134337.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Monogr Pathol. 1997;(39):118-33 [9249823.001]
  • [Cites] Diagn Mol Pathol. 1997 Jun;6(3):154-60 [9276187.001]
  • [Cites] Blood. 1998 Mar 1;91(5):1680-7 [9473234.001]
  • [Cites] Cancer Genet Cytogenet. 2003 May;143(1):73-9 [12742158.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):2960-71 [12784330.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4944-51 [12595313.001]
  • [Cites] Cytopathology. 2003 Aug;14(4):186-90 [12873310.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 [12900505.001]
  • [Cites] Br J Haematol. 2003 Sep;122(5):745-59 [12930384.001]
  • [Cites] Arch Pathol Lab Med. 2003 Sep;127(9):1148-60 [12946230.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Eur J Haematol. 2001 Feb;66(2):100-6 [11168517.001]
  • [Cites] Mol Diagn. 2000 Dec;5(4):287-99 [11172493.001]
  • [Cites] Blood. 2001 Apr 1;97(7):2098-104 [11264177.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Apr 1;126(1):26-33 [11343775.001]
  • [Cites] Mod Pathol. 2001 May;14(5):472-81 [11353059.001]
  • [Cites] Cytopathology. 2001 Jun;12(3):157-67 [11380557.001]
  • [Cites] J Clin Pathol. 2001 Jul;54(7):565-7 [11429433.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2001 Aug 20;60(2):135-40 [11518591.001]
  • [Cites] Mol Diagn. 2001 Sep;6(3):161-8 [11571709.001]
  • [Cites] Blood. 2002 Jan 15;99(2):716-8 [11781262.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Diagn Mol Pathol. 2002 Mar;11(1):47-57 [11854602.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):794-801 [11895911.001]
  • [Cites] Hematol J. 2000;1(1):53-66 [11920170.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R3 [12052255.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3):258-63 [12063678.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] Methods Mol Biol. 2002;204:143-53 [12397796.001]
  • [Cites] Blood. 2003 Mar 15;101(6):2363-7 [12424193.001]
  • [Cites] Cancer Cell. 2003 Feb;3(2):185-97 [12620412.001]
  • [Cites] Br J Haematol. 2003 Apr;121(1):49-56 [12670331.001]
  • [Cites] Diagn Cytopathol. 2003 Apr;28(4):191-5 [12672094.001]
  • [Cites] N Engl J Med. 2003 May 1;348(18):1777-85 [12724484.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):119-26 [15085740.001]
  • [Cites] Diagn Cytopathol. 2004 May;30(5):332-40 [15108231.001]
  • [Cites] Eur J Hum Genet. 2004 Jun;12(6):423 [15162123.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S13-20 [15202520.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):159-66 [15215171.001]
  • [Cites] Diagn Cytopathol. 2004 Jul;31(1):23-30 [15236260.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3046-52 [15284254.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):644-53 [15286744.001]
  • [Cites] Am J Hematol. 2003 Sep;74(1):78-84 [12949897.001]
  • [Cites] Leuk Lymphoma. 2003 Aug;44(8):1385-94 [12952233.001]
  • [Cites] Exp Hematol. 2003 Sep;31(9):784-8 [12962724.001]
  • [Cites] Acta Cytol. 2003 Sep-Oct;47(5):744-8 [14526672.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):296-307 [14582080.001]
  • [Cites] Blood. 2003 Dec 1;102(12):3871-9 [12933571.001]
  • [Cites] Histopathology. 2003 Dec;43(6):509-28 [14636252.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5980-7 [14676123.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):385-93 [14681948.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):131-5 [14657953.001]
  • [Cites] J Exp Med. 2004 Jan 5;199(1):59-68 [14707115.001]
  • [Cites] Lancet. 2004 Jan 10;363(9403):105-11 [14726163.001]
  • [Cites] Hematol J. 2004;5(1):69-76 [14745433.001]
  • [Cites] J Clin Oncol. 2004 Feb 1;22(3):474-83 [14752070.001]
  • [Cites] Pathology. 2004 Feb;36(1):19-44 [14757555.001]
  • [Cites] Semin Immunol. 1998 Apr;10(2):133-42 [9618759.001]
  • [Cites] Cancer. 1998 Aug 25;84(4):252-61 [9723601.001]
  • [Cites] Diagn Mol Pathol. 1998 Aug;7(4):209-14 [9917131.001]
  • [Cites] Cell. 1999 Jan 8;96(1):35-45 [9989495.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Diagn Cytopathol. 1999 Aug;21(2):98-104 [10425046.001]
  • [Cites] Diagn Cytopathol. 1999 Oct;21(4):240-9 [10495316.001]
  • [Cites] J Clin Lab Anal. 1999;13(5):224-8 [10494131.001]
  • (PMID = 15917402.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 90
  • [Other-IDs] NLM/ PMC1770685
  •  go-up   go-down


22. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein biomarker identification in the CSF of patients with CNS lymphoma.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • METHODS: We used a liquid chromatography/mass spectrometry-based method to differentially quantify and identify several hundred CSF proteins in CNS lymphoma and control patients.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


23. Gao X, Xue Z, Xing J, Lee DY, Gottschalk SM, Heslop HE, Bollard CM, Wong ST: Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging. Acad Radiol; 2010 Apr;17(4):479-88
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computer-assisted quantitative evaluation of therapeutic responses for lymphoma using serial PET/CT imaging.
  • RATIONALE AND OBJECTIVES: Molecular imaging modalities such as positron emission tomography (PET)/computed tomography (CT) have emerged as an essential diagnostic tool for monitoring treatment response in lymphoma patients.
  • We applied LINA retrospectively to nine lymphoma patients enrolled in an immunotherapy clinical trial conducted at the Center for Cell and Gene Therapy, Baylor College of Medicine.
  • [MeSH-major] Algorithms. Image Interpretation, Computer-Assisted / methods. Lymphoma / diagnosis. Lymphoma / therapy. Pattern Recognition, Automated / methods. Positron-Emission Tomography / methods. Subtraction Technique. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AUR. Published by Elsevier Inc. All rights reserved.
  • [Cites] IEEE Trans Med Imaging. 1999 Aug;18(8):712-21 [10534053.001]
  • [Cites] Comput Med Imaging Graph. 2010 Jan;34(1):55-60 [19709855.001]
  • [Cites] J Nucl Med. 2003 Feb;44(2):224-39 [12571214.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30 Suppl 1:S82-8 [12719922.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1200-9 [12902408.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Aug;22(8):1014-25 [12906255.001]
  • [Cites] Mol Imaging Biol. 2004 Jul-Aug;6(4):200-7 [15262235.001]
  • [Cites] J Nucl Med. 2004 Sep;45(9):1431-4 [15347707.001]
  • [Cites] IEEE Trans Pattern Anal Mach Intell. 2004 Mar;26(3):402-7 [15376886.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] J Nucl Med. 1995 Oct;36(10):1836-9 [7562051.001]
  • [Cites] Radiology. 2004 Nov;233(2):433-40 [15516617.001]
  • [Cites] J Nucl Med. 2005 Jul;46(7):1225-39 [16000293.001]
  • [Cites] Br J Radiol. 2006 Jan;79(937):32-6 [16421402.001]
  • [Cites] Med Image Anal. 2006 Oct;10(5):740-51 [16887376.001]
  • [Cites] Br J Haematol. 2006 Nov;135(3):293-302 [17032175.001]
  • [Cites] Med Phys. 2007 Jan;34(1):55-62 [17278490.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2838-45 [17609424.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2007;10(Pt 2):319-26 [18044584.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2465-71 [18551347.001]
  • [Cites] Mol Imaging Biol. 2008 Nov-Dec;10(6):306-14 [18665425.001]
  • [Cites] Med Image Comput Comput Assist Interv. 2008;11(Pt 2):989-97 [18982701.001]
  • [Cites] J Nucl Med. 2009 May;50 Suppl 1:1S-10S [19380403.001]
  • [Cites] J Nucl Med. 2009 May;50 Suppl 1:21S-30S [19380407.001]
  • [Cites] Mol Imaging Biol. 2009 Jul-Aug;11(4):269-74 [19326177.001]
  • [Cites] Ann Oncol. 2009 Sep;20(9):1543-7 [19474116.001]
  • [Cites] Med Image Anal. 2001 Jun;5(2):143-56 [11516708.001]
  • (PMID = 20060747.001).
  • [ISSN] 1878-4046
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA126752; United States / NCI NIH HHS / CA / P50 CA126752-01; United States / NCI NIH HHS / CA / P50 CA126752-02; United States / NCI NIH HHS / CA / P50 CA126752-03
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS169322; NLM/ PMC2846835
  • [Keywords] NOTNLM ; Lymphoma / PET/CT / longitudinal registration of serial images / quantitative evaluation of treatment outcomes
  •  go-up   go-down


24. Ramnath V, Rekha PS, Kuttan G, Kuttan R: Regulation of Caspase-3 and Bcl-2 Expression in Dalton's Lymphoma Ascites Cells by Abrin. Evid Based Complement Alternat Med; 2009 Jun;6(2):233-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulation of Caspase-3 and Bcl-2 Expression in Dalton's Lymphoma Ascites Cells by Abrin.
  • The role of abrin, a toxic lectin isolated from seeds of Abrus precatorius Linn in inducing apoptosis in murine Dalton's Lymphoma Ascites (DLA) cells was evaluated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biotechniques. 1996 Dec;21(6):1094-100 [8969838.001]
  • [Cites] Cancer Res. 1997 Apr 1;57(7):1301-5 [9102217.001]
  • [Cites] FASEB J. 1994 Jun;8(9):654-60 [8005393.001]
  • [Cites] Anal Biochem. 1991 Apr;194(1):101-9 [1867374.001]
  • [Cites] J Immunol. 1989 Mar 1;142(5):1755-66 [2465347.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2755-8 [3552205.001]
  • [Cites] Nucleic Acids Symp Ser. 1986;(17):187-90 [3562265.001]
  • [Cites] J Cell Physiol. 1985 Apr;123(1):132-8 [3972909.001]
  • [Cites] Pharmacol Biochem Behav. 1982 Jan;16(1):185-8 [6276906.001]
  • [Cites] Cancer Res. 1982 Jan;42(1):276-9 [7053854.001]
  • [Cites] J Biol Chem. 1974 Jun 10;249(11):3557-62 [4208663.001]
  • [Cites] Cell. 1975 Mar;4(3):263-8 [1122556.001]
  • [Cites] J Biochem Mol Biol. 2004 Jul 31;37(4):445-53 [15469732.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Mar 1;195(2):182-93 [14998684.001]
  • [Cites] Biochem J. 2004 Jan 1;377(Pt 1):233-40 [13129434.001]
  • [Cites] Indian J Exp Biol. 2002 Aug;40(8):910-3 [12597021.001]
  • [Cites] Indian J Physiol Pharmacol. 2002 Jan;46(1):69-77 [12024960.001]
  • [Cites] Int J Biochem Cell Biol. 2000 Mar;32(3):317-26 [10716629.001]
  • [Cites] J Biol Chem. 2006 Nov 10;281(45):34465-74 [16772301.001]
  • [Cites] Immunopharmacol Immunotoxicol. 2006;28(2):259-68 [16873094.001]
  • [Cites] Toxicol Lett. 1997 Apr 28;91(2):121-7 [9175848.001]
  • [Cites] Biosci Biotechnol Biochem. 1997 Apr;61(4):737-9 [9145534.001]
  • [Cites] J Cell Biochem Suppl. 1995;22:151-61 [8538193.001]
  • (PMID = 18955274.001).
  • [ISSN] 1741-427X
  • [Journal-full-title] Evidence-based complementary and alternative medicine : eCAM
  • [ISO-abbreviation] Evid Based Complement Alternat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2686625
  • [Keywords] NOTNLM ; Bcl-2 / Caspase-3 / abrin / apoptosis / p53
  •  go-up   go-down


25. Tavora F, Gonzalez-Cuyar LF, Sun CC, Burke A, Zhao XF: Extra-oral plasmablastic lymphoma: report of a case and review of literature. Hum Pathol; 2006 Sep;37(9):1233-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-oral plasmablastic lymphoma: report of a case and review of literature.
  • Plasmablastic lymphoma (PBL) of the oral cavity is classified as one subtype of diffuse large B-cell lymphoma that is most commonly seen in patients with human immunodeficiency virus infection.
  • We report a rare case of PBL in the anal canal of a 33-year-old man with human immunodeficiency virus infection.
  • The lymphoma cells were positive for CD138 and weakly positive for CD79a.
  • We propose that the term plasmablastic lymphoma of the oral cavity in World Health Organization classification be revised to simply plasmablastic lymphoma, which would include both oral and extra-oral PBLs, and the term to define the primary site of the lymphoma (ie, oral cavity) be dropped from the terminology used in World Health Organization classification.
  • [MeSH-major] Anus Neoplasms / classification. Anus Neoplasms / pathology. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16938530.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD79; 0 / Membrane Glycoproteins; 0 / Proteoglycans; 0 / SDC1 protein, human; 0 / Syndecan-1; 0 / Syndecans; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


26. Crockett DK, Seiler CE 3rd, Elenitoba-Johnson KS, Lim MS: Annotated proteome of a human T-cell lymphoma. J Biomol Tech; 2005 Dec;16(4):341-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Annotated proteome of a human T-cell lymphoma.
  • Our goal was to survey the proteome of a human T-cell lymphoma-derived cell line in a single set of experiments and present an automated method for the annotation of lists of proteins.
  • A downstream application of these data includes the identification of novel pathogenetic and candidate diagnostic markers of T-cell lymphoma.
  • Total protein isolated from cytoplasmic, membrane, and nuclear fractions of the SUDHL-1 T-cell lymphoma cell line was resolved by SDS-PAGE, and the entire gel lanes digested and analyzed by tandem mass spectrometry.
  • A total of 1105 unique proteins were identified and fully annotated, including numerous proteins that had not been previously characterized in lymphoma, in functional categories such as cell adhesion, migration, signaling, and stress response.
  • [MeSH-major] Biomarkers, Tumor. Lymphoma, T-Cell / chemistry. Proteins / analysis. Proteome / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Biotechniques. 1989 Oct;7(9):946-8, 950-4, 956-8 [2483665.001]
  • [Cites] Gene Anal Tech. 1989 Sep-Oct;6(5):101-9 [2555292.001]
  • [Cites] Cancer. 1974 Dec;34(6):1851-72 [4140017.001]
  • [Cites] J Biomol Tech. 2003 Jun;14(2):149-55 [14676314.001]
  • [Cites] Anal Chem. 2003 Sep 1;75(17):4646-58 [14632076.001]
  • [Cites] Genome Biol. 2003;4(4):R28 [12702209.001]
  • (PMID = 16522855.001).
  • [ISSN] 1524-0215
  • [Journal-full-title] Journal of biomolecular techniques : JBT
  • [ISO-abbreviation] J Biomol Tech
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Extracts; 0 / Proteins; 0 / Proteome; EC 3.4.21.4 / Trypsin
  • [Other-IDs] NLM/ PMC2291739
  •  go-up   go-down


27. Degeorges S, Mesnil A, Marion-Audibert AM, Bouafia-Sauvy F, Berger F, Bancel B, Barnoud R, Rode A, Péré-Vergé D, Souquet JC: [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient]. Gastroenterol Clin Biol; 2007 Apr;31(4):442-4
Genetic Alliance. consumer health - Burkitt's Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ano-rectal symptoms, related to Epstein-Barr Virus-Associated Burkitt's lymphoma in an immunocompetent patient].
  • We report the case of an immunocompetent 23-year-old Caucasian woman, with symptoms including rectal bleeding, tenesmus and epreint, 6 months after an anal sexual trauma.
  • The rectal examination showed a hardened, inflammatory and painful anal margin, associated with stenosis of the anal canal, suggesting abscess.
  • Pelvic MRI and CT scan confirmed a bulky posterior tissular pelvic mass more than 7 cm in diameter, infiltrating the rectum and the anal canal.
  • Final diagnosis confirmed by biopsy performed during rectosigmoidoscopy was an Epstein-Barr Virus-Associated Burkitt's lymphoma.
  • [MeSH-major] Burkitt Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483786.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Richardson DB, Sugiyama H, Wing S, Sakata R, Grant E, Shimizu Y, Nishi N, Geyer S, Soda M, Suyama A, Kasagi F, Kodama K: Positive associations between ionizing radiation and lymphoma mortality among men. Am J Epidemiol; 2009 Apr 15;169(8):969-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Positive associations between ionizing radiation and lymphoma mortality among men.
  • The authors investigated the relation between ionizing radiation and lymphoma mortality in 2 cohorts:.
  • Radiation dose-mortality trends were evaluated for all malignant lymphomas and for non-Hodgkin's lymphoma.
  • Positive associations between lymphoma mortality and radiation dose under a 5-year lag assumption were observed in both cohorts (excess relative rates per sievert were 0.79 (90% confidence interval: 0.10, 1.88) and 6.99 (90% confidence interval: 0.96, 18.39), respectively).
  • These findings suggest a protracted induction and latency period for radiation-induced lymphoma mortality.
  • [MeSH-major] Environmental Exposure / analysis. Environmental Monitoring / statistics & numerical data. Lymphoma / mortality. Nuclear Warfare / statistics & numerical data. Nuclear Weapons / statistics & numerical data. Radioactive Fallout / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Epidemiology. 1991 Nov;2(6):418-23 [1790193.001]
  • [Cites] Radiat Res. 1990 Sep;123(3):275-84 [2217725.001]
  • [Cites] Radiat Res. 1993 Dec;136(3):408-21 [8278584.001]
  • [Cites] Epidemiology. 1994 Mar;5(2):189-96 [8172994.001]
  • [Cites] Am J Epidemiol. 1996 Jan 15;143(2):202-10 [8546122.001]
  • [Cites] Radiat Res. 1996 Jul;146(1):1-27 [8677290.001]
  • [Cites] Radiat Res. 1998 Nov;150(5 Suppl):S30-41 [9806607.001]
  • [Cites] J Radiol Prot. 1999 Mar;19(1):3-26 [10321692.001]
  • [Cites] Radiat Res. 1999 Oct;152(4):374-89 [10477914.001]
  • [Cites] Radiat Prot Dosimetry. 2005;113(3):275-89 [15769802.001]
  • [Cites] BMJ. 2005 Jul 9;331(7508):77 [15987704.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2005 Sep;15(5):398-406 [15592443.001]
  • [Cites] Radiat Prot Dosimetry. 2006;118(1):43-55 [16081492.001]
  • [Cites] Radiat Prot Dosimetry. 2006;121(3):240-51 [16517566.001]
  • [Cites] J Expo Sci Environ Epidemiol. 2007 Jan;17(1):13-24 [16804558.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):385-91 [17337645.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):367-8 [17344463.001]
  • [Cites] Radiat Res. 2007 Apr;167(4):396-416 [17388693.001]
  • [Cites] Radiat Res. 2007 Feb;167(2):222-32 [17390730.001]
  • [Cites] Radiat Res. 2007 Jun;167(6):735-41 [17523841.001]
  • [Cites] Epidemiology. 2007 Jul;18(4):453-60 [17473709.001]
  • [Cites] Radiat Res. 2007 Jul;168(1):1-64 [17722996.001]
  • [Cites] Am J Epidemiol. 2007 Nov 1;166(9):1015-22 [17660455.001]
  • [Cites] Int J Epidemiol. 2000 Aug;29(4):708-14 [10922349.001]
  • [Cites] Radiat Res. 2004 Oct;162(4):377-89 [15447045.001]
  • [Cites] Radiat Res. 1990 Feb;121(2):120-41 [2305030.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5489s-5491s [1394160.001]
  • (PMID = 19270049.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Grant] United States / NIOSH CDC HHS / OH / R01 OH007871
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioactive Fallout
  • [Other-IDs] NLM/ PMC2732978
  •  go-up   go-down


29. Liu J, Lau SK, Varma VA, Kairdolf BA, Nie S: Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots. Anal Chem; 2010 Jul 15;82(14):6237-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots.
  • Here, we report the use of multiplexed QDs and wavelength-resolved imaging to detect and characterize a class of low-abundant tumor cells in Hodgkin's lymphoma.
  • We have also carried out clinical translation studies involving six confirmed Hodgkin's lymphoma patients, two suspicious lymphoma cases, and two patients with reactive lymph nodes (but not lymphoma).
  • The results indicate that a distinct QD staining pattern (CD15 positive, CD30 positive, CD45 negative, and Pax5 positive) can be used to not only detect Hodgkin's lymphoma but also differentiate it from benign lymphoid hyperplasia.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] ACS Nano. 2010 May 25;4(5):2755-65 [20377268.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):162-76 [11896065.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Cancer Detect Prev. 2002;26(4):249-55 [12430629.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117 Suppl:S76-94 [14569804.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):47-52 [14704706.001]
  • [Cites] J Clin Pathol. 1987 Nov;40(11):1298-304 [3320093.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2905-17 [8639911.001]
  • [Cites] J Pathol. 1997 Apr;181(4):462-3 [9196447.001]
  • [Cites] Mol Med Today. 1995 Apr;1(1):26-30 [9415134.001]
  • [Cites] Science. 2005 Jan 28;307(5709):538-44 [15681376.001]
  • [Cites] Curr Opin Biotechnol. 2005 Feb;16(1):63-72 [15722017.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41207 [16178631.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Mar;6(2):231-44 [16512782.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1181-91 [16778828.001]
  • [Cites] Nano Lett. 2006 Dec;6(12):2881-6 [17163724.001]
  • [Cites] Nat Protoc. 2007;2(5):1152-65 [17546006.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):871-7 [17529924.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:257-88 [17439359.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1226-40 [18495291.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 19;374(2):181-6 [18621021.001]
  • [Cites] J Pathol. 2008 Nov;216(3):275-85 [18814189.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Nat Methods. 2009 Feb;6(2):139-41 [19137005.001]
  • [Cites] Biomaterials. 2009 May;30(15):2912-8 [19251316.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Trends Biotechnol. 2009 Jun;27(6):350-8 [19409634.001]
  • [Cites] Biosens Bioelectron. 2009 Aug 15;24(12):3657-62 [19540102.001]
  • [Cites] J Mol Histol. 2009 Aug;40(4):261-8 [19908148.001]
  • [Cites] ACS Nano. 2010 Jan 26;4(1):488-94 [20041634.001]
  • [Cites] N Engl J Med. 2010 Mar 11;362(10):875-85 [20220182.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • (PMID = 20565106.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108468; United States / NCI NIH HHS / CA / CA119338-01; United States / NCI NIH HHS / CA / U54CA119338; United States / NCI NIH HHS / CA / U54 CA119338; United States / NCI NIH HHS / CA / CA108468-01; United States / NCI NIH HHS / CA / R01 CA108468-01; United States / NCI NIH HHS / CA / R01CA108468; United States / NCI NIH HHS / CA / U54 CA119338-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS220487; NLM/ PMC2914471
  •  go-up   go-down


30. Colt JS, Rothman N, Severson RK, Hartge P, Cerhan JR, Chatterjee N, Cozen W, Morton LM, De Roos AJ, Davis S, Chanock S, Wang SS: Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma. Blood; 2009 Feb 26;113(9):1899-905
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organochlorine exposure, immune gene variation, and risk of non-Hodgkin lymphoma.
  • Organochlorine exposure was linked to non-Hodgkin lymphoma (NHL) risk.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5545-52 [17545638.001]
  • [Cites] Lancet. 1997 Jul 26;350(9073):240-4 [9242800.001]
  • [Cites] Cancer Causes Control. 2007 Oct;18(8):821-31 [17588155.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4455-63 [17827388.001]
  • [Cites] Am J Epidemiol. 1997 Jun 15;145(12):1061-75 [9199536.001]
  • [Cites] Environ Health Perspect. 2000 Dec;108(12):1203-7 [11133402.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):619-29 [11697490.001]
  • [Cites] Environ Health Perspect. 2002 Jun;110(6):595-600 [12055051.001]
  • [Cites] Leuk Lymphoma. 2002 Jun;43(6):1203-10 [12152987.001]
  • [Cites] Food Chem Toxicol. 2003 Jan;41(1):107-18 [12453735.001]
  • [Cites] Am J Hum Genet. 2003 Jun;72(6):1505-14 [12748907.001]
  • [Cites] Clin Immunol. 2003 Nov;109(2):119-29 [14597210.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1997;69:1-631 [9379504.001]
  • [Cites] Environ Health Perspect. 1998 Dec;106(12):775-92 [9831538.001]
  • [Cites] Environ Health Perspect. 2004 Dec;112(17):1691-6 [15579415.001]
  • [Cites] Epidemiology. 2005 Jul;16(4):516-25 [15951670.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11214-26 [16322272.001]
  • [Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):251-7 [16492912.001]
  • [Cites] Blood. 2006 May 15;107(10):4101-8 [16449530.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9771-80 [17018637.001]
  • [Cites] Mol Hum Reprod. 2007 Feb;13(2):135-40 [17178764.001]
  • [Cites] Chemosphere. 2007 Apr;67(9):S393-8 [17222440.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):704-12 [17056605.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):5042-54 [17510437.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2004 Jan;14(1):74-83 [14726946.001]
  • [Cites] Environ Health Perspect. 2004 Jun;112(8):854-61 [15175172.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1415-21 [15342441.001]
  • [Cites] N Engl J Med. 1991 Jan 24;324(4):212-8 [1985242.001]
  • [Cites] Am J Ind Med. 1990;18(6):665-73 [2264565.001]
  • [Cites] Arch Environ Health. 1992 Jul-Aug;47(4):295-301 [1497384.001]
  • [Cites] Epidemiology. 1993 Sep;4(5):398-406 [8399687.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Exp Clin Immunogenet. 1994;11(2-3):149-62 [7826664.001]
  • [Cites] Environ Health Perspect. 1995 Mar;103 Suppl 2:135-42 [7614935.001]
  • [Cites] Pediatr Res. 1995 Sep;38(3):404-10 [7494667.001]
  • [Cites] Am J Ophthalmol. 1995 Nov;120(5):671-3 [7485372.001]
  • [Cites] Eur J Immunogenet. 1997 Feb;24(1):1-8 [9043871.001]
  • [Cites] Haematologica. 2007 Jul;92(7):960-9 [17606447.001]
  • (PMID = 19066394.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01 PC067009; United States / NCI NIH HHS / CN / N01-CN-67008; United States / NCI NIH HHS / PC / N01-PC-65064; United States / NCI NIH HHS / CP / Y1-CP-8028-02; United States / NCI NIH HHS / PC / N01-PC-67009; United States / Intramural NIH HHS / / ; None / None / / N01 PC065064; United States / NCI NIH HHS / CP / N02-CP-19 114; United States / NCI NIH HHS / CN / N01-CN-67010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydrocarbons, Chlorinated; 0 / Interleukins; 35065-29-3 / PCB 180; DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ PMC2651009
  •  go-up   go-down


31. Abraham MG, Levin KA, Balasubramanian M, Minimo C, Galindo LM, Hou JS: Diagnosis of T-cell lymphoma in body fluids: cytologic features and unusual flow cytometric findings. Anal Quant Cytol Histol; 2007 Oct;29(5):333-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of T-cell lymphoma in body fluids: cytologic features and unusual flow cytometric findings.
  • STUDY DESIGN: Cytologic slides and flow cytometric histograms of 8 cases of body fluids with T-cell lymphoma were retrospectively reviewed.
  • The remaining cases showed the conventional morphologic and flow cytometric features of a T-cell lymphoma.
  • The unusual flow cytometric histogram can serve as a useful clue for the diagnosis of T-cell lymphoma in body fluids but could be a potential pitfall for a false negative.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17987814.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Baek T, Huh J, Kwak H, Park M, Lee H: Image analytic study of nuclear area in mantle cell lymphoma. Korean J Hematol; 2010 Sep;45(3):193-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image analytic study of nuclear area in mantle cell lymphoma.
  • METHODS: Twenty specimens of mantle cell lymphoma and 2 specimens of the tonsil were examined.
  • The nuclear area of 6,401 tumor cells of mantle cell lymphoma and 743 normal mantle cells of reactive tonsils were measured by 3 authors by using a user-controlled image-analyzer.
  • RESULTS: The mean nuclear areas of mantle cell lymphoma cells measured by the 3 authors were 37.9 [7.9] µm(2), 37.9 [7.2] µm(2), and 38.2 [7.7] µm(2) and those of normal mantle cells in reactive tonsil were 28.6 [2.3] µm(2), 28.8 [2.0] µm(2), and 27.0 [3.0] µm(2).
  • There was no statistical difference between the 3 observations of mantle cell lymphoma (P=0.580) and normal tonsils.
  • CONCLUSION: For morphology, nuclear area is considered an important feature in the classification schemes of lymphoma.
  • We think that nuclear morphometry may play a significant role in the diagnosis of lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1979 Jul;32(7):670-4 [583049.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1415-25 [6895048.001]
  • [Cites] Cancer. 1982 Apr 1;49(7):1429-38 [6895860.001]
  • [Cites] J Clin Pathol. 1982 Sep;35(9):954-8 [7119128.001]
  • [Cites] J Clin Pathol. 1983 Mar;36(3):289-97 [6600749.001]
  • [Cites] Anal Quant Cytol Histol. 2007 Oct;29(5):309-16 [17987811.001]
  • [Cites] J Clin Pathol. 1983 Dec;36(12):1332-4 [6361071.001]
  • [Cites] J Clin Pathol. 2008 Feb;61(2):209-12 [17496190.001]
  • [Cites] Blood. 2008 Dec 1;112(12):4384-99 [19029456.001]
  • [Cites] J Pathol. 1984 Jun;143(2):69-80 [6376742.001]
  • [Cites] J Clin Pathol. 1983 Mar;36(3):298-302 [6338055.001]
  • (PMID = 21120209.001).
  • [ISSN] 2092-9129
  • [Journal-full-title] The Korean journal of hematology
  • [ISO-abbreviation] Korean J Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2983036
  • [Keywords] NOTNLM ; Image analysis / Mantle cell lymphoma / Morphometry / Nuclear area
  •  go-up   go-down


33. Kristiansson MH, Bhat VB, Babu IR, Wishnok JS, Tannenbaum SR: Comparative time-dependent analysis of potential inflammation biomarkers in lymphoma-bearing SJL mice. J Proteome Res; 2007 May;6(5):1735-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative time-dependent analysis of potential inflammation biomarkers in lymphoma-bearing SJL mice.
  • SJL mice colonized with RcsX lymphoma cells undergo a rapid inflammatory response associated with biological and physiological effects including increased nitric oxide production and mutations in spleen DNA.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Periodontol 2000. 2000 Jun;23:19-49 [11276764.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2000-9 [16199891.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):833-9 [11891182.001]
  • [Cites] Mol Cell Proteomics. 2002 Nov;1(11):845-67 [12488461.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8135-45 [12506115.001]
  • [Cites] Pharmacol Rev. 2003 Sep;55(3):551-71 [12869663.001]
  • [Cites] Anal Biochem. 2003 Sep 15;320(2):214-22 [12927827.001]
  • [Cites] Glycoconj J. 2002 May-Jun;19(4-5):241-7 [12975601.001]
  • [Cites] Arch Biochem Biophys. 2004 Mar 1;423(1):12-22 [14989259.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Electrophoresis. 2004 Sep;25(17):3055-65 [15349948.001]
  • [Cites] Clin Exp Immunol. 1978 Apr;32(1):119-24 [668189.001]
  • [Cites] Cell Immunol. 1981 Nov 15;65(1):84-92 [7032709.001]
  • [Cites] Am J Gastroenterol. 1982 Jun;77(6):427-30 [7091128.001]
  • [Cites] J Natl Cancer Inst. 1984 Feb;72(2):311-20 [6420599.001]
  • [Cites] J Biol Chem. 1985 Dec 15;260(29):15604-9 [3864781.001]
  • [Cites] J Immunol. 1988 Jan 15;140(2):679-87 [3275720.001]
  • [Cites] Biochem Biophys Res Commun. 1988 Mar 30;151(3):1364-70 [2895647.001]
  • [Cites] Cell Immunol. 1990 Sep;129(2):494-502 [2383901.001]
  • [Cites] J Cell Biochem. 1991 May;46(1):21-6 [1908473.001]
  • [Cites] EMBO J. 1991 Oct;10(10):2839-48 [1915266.001]
  • [Cites] J Appl Physiol (1985). 1992 Jan;72(1):1-7 [1371501.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Sep 15;89(18):8616-20 [1528870.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3226-33 [7685199.001]
  • [Cites] EMBO J. 1993 Jun;12(6):2313-20 [8389694.001]
  • [Cites] Am J Physiol Cell Physiol. 2006 Jan;290(1):C95-C103 [16120654.001]
  • [Cites] Rapid Commun Mass Spectrom. 2006;20(7):1127-34 [16521170.001]
  • [Cites] DNA Cell Biol. 2006 Jun;25(6):323-30 [16792502.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1727-44 [16887931.001]
  • [Cites] FEBS Lett. 1993 Nov 15;334(2):193-7 [7901054.001]
  • [Cites] Immunol Today. 1994 Feb;15(2):74-80 [7512342.001]
  • [Cites] J Biochem. 1994 Mar;115(3):557-62 [8056772.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11499-503 [8876164.001]
  • [Cites] Muscle Nerve. 1997 Jan;20(1):72-82 [8995586.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1823-8 [9157968.001]
  • [Cites] Stem Cells. 1999;17(3):127-37 [10342555.001]
  • [Cites] Mol Cell Proteomics. 2004 Dec;3(12):1154-69 [15385600.001]
  • [Cites] Proteomics. 2005 Feb;5(2):572-84 [15627965.001]
  • [Cites] Toxicol Pathol. 2005;33(1):52-62 [15805056.001]
  • [Cites] Mol Cell Proteomics. 2005 May;4(5):700-9 [15753121.001]
  • [Cites] Mol Cell Proteomics. 2005 Jul;4(7):924-35 [15849271.001]
  • [Cites] J Proteome Res. 2005 Sep-Oct;4(5):1814-25 [16212437.001]
  • [Cites] Proteomics. 2005 Oct;5(15):4012-24 [16130168.001]
  • [Cites] Proteomics. 2005 Oct;5(15):3991-4000 [16130172.001]
  • [Cites] Proteomics. 2005 Nov;5(16):4245-53 [16196095.001]
  • [Cites] Curr Opin Crit Care. 2001 Apr;7(2):99-104 [11373518.001]
  • (PMID = 17388619.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30-ES02109; United States / NCI NIH HHS / CA / CA026731-29; United States / NCI NIH HHS / CA / P01 CA026731-29; United States / NIEHS NIH HHS / ES / P30 ES002109; United States / NCI NIH HHS / CA / P01-CA26731; United States / NCI NIH HHS / CA / P01 CA026731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Proteome
  • [Other-IDs] NLM/ NIHMS62938; NLM/ PMC2532589
  •  go-up   go-down


34. Sriram MI, Kanth SB, Kalishwaralal K, Gurunathan S: Antitumor activity of silver nanoparticles in Dalton's lymphoma ascites tumor model. Int J Nanomedicine; 2010;5:753-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antitumor activity of silver nanoparticles in Dalton's lymphoma ascites tumor model.
  • The present study demonstrates the efficacy of biologically synthesized silver nanoparticles (AgNPs) as an antitumor agent using Dalton's lymphoma ascites (DLA) cell lines in vitro and in vivo.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Lymphoma / drug therapy. Metal Nanoparticles / administration & dosage. Silver / administration & dosage

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. SILVER, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Burns. 2000 Mar;26(2):117-30 [10716354.001]
  • [Cites] Bioconjug Chem. 2009 Aug 19;20(8):1497-502 [21141805.001]
  • [Cites] Burns. 2004 Jul;30 Suppl 1:S1-9 [15327800.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):360-8 [7812969.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):376-85 [7529135.001]
  • [Cites] J Antimicrob Chemother. 2004 Dec;54(6):1019-24 [15537697.001]
  • [Cites] Arch Immunol Ther Exp (Warsz). 2005 Jan-Feb;53(1):47-60 [15761376.001]
  • [Cites] J Nanosci Nanotechnol. 2005 Feb;5(2):244-9 [15853142.001]
  • [Cites] Chem Commun (Camb). 2005 Oct 28;(40):5059-61 [16220170.001]
  • [Cites] J Ind Microbiol Biotechnol. 2006 Jul;33(7):627-34 [16761169.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):657-67 [16887483.001]
  • [Cites] Nat Biotechnol. 2006 Oct;24(10):1211-7 [17033654.001]
  • [Cites] Nanomedicine. 2007 Mar;3(1):95-101 [17379174.001]
  • [Cites] Drug Discov Today. 2008 Feb;13(3-4):144-51 [18275912.001]
  • [Cites] Nat Mater. 2008 Mar;7(3):236-41 [18204453.001]
  • [Cites] Antivir Ther. 2008;13(2):253-62 [18505176.001]
  • [Cites] Toxicol Lett. 2008 Jun 30;179(2):93-100 [18508209.001]
  • [Cites] Colloids Surf B Biointerfaces. 2008 Aug 1;65(1):150-3 [18406112.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1289-306 [18501989.001]
  • [Cites] Anal Chem. 2008 Sep 1;80(17):6620-5 [18642876.001]
  • [Cites] Dokl Biochem Biophys. 2008 Jul-Aug;421:191-3 [18853769.001]
  • [Cites] Analyst. 2009 Mar;134(3):425-39 [19238274.001]
  • [Cites] Environ Health Perspect. 2009 Apr;117(4):A158-61 [19440480.001]
  • [Cites] Colloids Surf B Biointerfaces. 2009 Oct 1;73(1):51-7 [19481908.001]
  • [Cites] Biomaterials. 2009 Oct;30(31):6341-50 [19698986.001]
  • [Cites] Colloids Surf B Biointerfaces. 2009 Nov 1;74(1):328-35 [19716685.001]
  • [Cites] Biotechnol Adv. 2009 Nov-Dec;27(6):924-37 [19686832.001]
  • [Cites] Biomacromolecules. 2009 Mar 9;10(3):589-95 [19226107.001]
  • [Cites] Biomaterials. 2010 Mar;31(8):2260-71 [19963272.001]
  • [Cites] Int J Nanomedicine. 2010;5:77-85 [20161989.001]
  • [Cites] Colloids Surf B Biointerfaces. 2010 Jun 1;77(2):257-62 [20197229.001]
  • [Cites] J Control Release. 2010 Jul 14;145(2):76-90 [20359511.001]
  • [Cites] J Colloid Interface Sci. 2004 Jul 1;275(1):177-82 [15158396.001]
  • (PMID = 21042421.001).
  • [ISSN] 1178-2013
  • [Journal-full-title] International journal of nanomedicine
  • [ISO-abbreviation] Int J Nanomedicine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3M4G523W1G / Silver; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2962271
  • [Keywords] NOTNLM ; Dalton’s lymphoma / antitumor / ascites / silver nanoparticles
  •  go-up   go-down


35. Elenitoba-Johnson KS, Crockett DK, Schumacher JA, Jenson SD, Coffin CM, Rockwood AL, Lim MS: Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins. Proc Natl Acad Sci U S A; 2006 May 9;103(19):7402-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.
  • The anaplastic lymphoma kinase (ALK) on 2p23 is a tyrosine kinase that forms chimeric fusions with numerous translocation partners.
  • This approach accurately identified the nucleophosmin (NPM)-ALK fusion protein in an anaplastic large cell lymphoma (ALCL)-derived cell line carrying the t(2;5)(p23;q35), and the TPM3-ALK in a clinical biopsy of inflammatory myofibroblastic tumor (IMT) carrying the t(1;2)(q21;p23).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1057-62 [9500471.001]
  • [Cites] J Biomol Tech. 2005 Dec;16(4):453-8 [16522868.001]
  • [Cites] Anal Chem. 2000 Feb 15;72(4):757-63 [10701260.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] Curr Opin Hematol. 2001 Jul;8(4):231-6 [11561161.001]
  • [Cites] Anal Chem. 2001 Dec 1;73(23):5683-90 [11774908.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):245-50 [11902580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7900-5 [12060738.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):361-70 [15122207.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Sep;5(9):699-711 [15340378.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):8998-9002 [2461560.001]
  • [Cites] Genetics. 1988 Nov;120(3):621-3 [2852134.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 11;20(3):595-600 [1371352.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Oct 15;63(2):81-8 [1423235.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):143-9 [7969446.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] PCR Methods Appl. 1994 Aug;4(1):S40-58 [9018326.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] Oncogene. 1997 May 8;14(18):2175-88 [9174053.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2456-64 [9310498.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11583-8 [9326653.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • (PMID = 16651537.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / TPM3 protein, human; 0 / Tropomyosin; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC1464352
  •  go-up   go-down


36. Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K: Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol Blood Marrow Transplant; 2008 Feb;14(2):236-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning.
  • Reduced-intensity conditioning (RIC) regimens have been increasingly used for allogeneic hematopoietic stem cell transplantation (HSCT) in follicular lymphoma (FL).
  • On multivariate analysis, an increased risk of lymphoma progression after RIC was observed (relative risk = 2.97, P = .04).

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2001 Feb 1;97(3):631-7 [11157478.001]
  • [Cites] Blood. 2006 Aug 1;108(3):836-46 [16597592.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:375-91 [11722994.001]
  • [Cites] Bone Marrow Transplant. 2001 Dec;28(11):1001-11 [11781608.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1309-10 [11965278.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4310-6 [12393626.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Jan;9(1):52-9 [12533742.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3521-9 [12893748.001]
  • [Cites] Blood. 2004 Jan 15;103(2):428-34 [12969983.001]
  • [Cites] Semin Oncol. 2004 Feb;31(1):22-6 [14970933.001]
  • [Cites] Blood. 2004 Aug 15;104(4):961-8 [15113759.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1550-8 [15150081.001]
  • [Cites] Transplantation. 1982 Oct;34(4):226-8 [6755835.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4288-90 [16946302.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34 [17162215.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3588-94 [17158231.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):140-7 [7799014.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1096-102 [7738615.001]
  • [Cites] Blood. 1998 Feb 1;91(3):756-63 [9446633.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1832-6 [9716615.001]
  • [Cites] Blood. 2004 Dec 15;104(13):3865-71 [15304395.001]
  • [Cites] Leukemia. 2005 Jun;19(6):1029-33 [15830011.001]
  • [Cites] Lifetime Data Anal. 2001 Sep;7(3):243-54 [11677829.001]
  • (PMID = 18215784.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U24 CA076518; United States / NCI NIH HHS / CA / U24 CA076518-10; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS39954; NLM/ PMC2531158
  •  go-up   go-down


37. Ghobrial IM, McCormick DJ, Kaufmann SH, Leontovich AA, Loegering DA, Dai NT, Krajnik KL, Stenson MJ, Melhem MF, Novak AJ, Ansell SM, Witzig TE: Proteomic analysis of mantle-cell lymphoma by protein microarray. Blood; 2005 May 1;105(9):3722-30
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic analysis of mantle-cell lymphoma by protein microarray.
  • Mantle-cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin lymphoma (NHL) that behaves aggressively and remains incurable.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 1993 Jan;120(2):313-23 [8421051.001]
  • [Cites] Mol Cell Biol. 1992 Aug;12(8):3337-45 [1630449.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2124-30 [8187765.001]
  • [Cites] Biochem J. 1995 Oct 1;311 ( Pt 1):17-29 [7575450.001]
  • [Cites] Leuk Lymphoma. 1996 May;21(5-6):391-7, color plates XVI following 5 [9172803.001]
  • [Cites] Blood. 1997 Mar 15;89(6):2067-78 [9058729.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1922-30 [9586911.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):329-36 [9640217.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29706-11 [9792683.001]
  • [Cites] Adv Anat Pathol. 1998 Nov;5(6):376-98 [10095879.001]
  • [Cites] Genes Dev. 1999 Oct 15;13(20):2658-69 [10541552.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:127-30 [10707794.001]
  • [Cites] Am J Hematol. 2000 Jul;64(3):190-6 [10861815.001]
  • [Cites] J Immunother. 2000 Sep-Oct;23(5):519-27 [11001545.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3922-31 [11090079.001]
  • [Cites] Am J Hematol. 2001 Jun;67(2):84-92 [11343379.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2171-7 [11360201.001]
  • [Cites] Pathol Int. 2001 Oct;51(10):747-61 [11881727.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):304-13 [12096112.001]
  • [Cites] Histopathology. 2002 Oct;41(4):322-30 [12383214.001]
  • [Cites] Haematologica. 2002 Nov;87(11):1141-50 [12414343.001]
  • [Cites] Curr Opin Chem Biol. 2003 Feb;7(1):55-63 [12547427.001]
  • [Cites] EMBO J. 2003 Mar 17;22(6):1442-50 [12628936.001]
  • [Cites] Electrophoresis. 2003 Jul;24(14):2376-85 [12874873.001]
  • [Cites] Mass Spectrom Rev. 2003 Jul-Aug;22(4):272-84 [12884390.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7777-84 [14633703.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8226-32 [14678979.001]
  • [Cites] J Immunol. 2004 Jan 1;172(1):274-81 [14688335.001]
  • [Cites] Breast Cancer Res Treat. 2004 Mar;84(1):13-9 [14999150.001]
  • [Cites] J Leukoc Biol. 2004 May;75(5):772-6 [14982944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8625-30 [15173575.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6807-20 [15501957.001]
  • [Cites] Leukemia. 1991 Sep;5(9):733-7 [1943225.001]
  • [Cites] Nature. 1991 Nov 7;354(6348):80-2 [1944575.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10830-4 [1961752.001]
  • [Cites] Anal Quant Cytol Histol. 1993 Jun;15(3):179-86 [8347257.001]
  • (PMID = 15650054.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA15083-29C1; United States / NCI NIH HHS / CA / CA97274
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC1895014
  •  go-up   go-down


38. Schumacher MA, Schmitz R, Brune V, Tiacci E, Döring C, Hansmann ML, Siebert R, Küppers R: Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma. Haematologica; 2010 Jan;95(1):153-7
Cellosaurus - a cell line knowledge resource. culture/stock collections - DEV (CVCL_7187) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mutations in the genes coding for the NF-κB regulating factors IκBα and A20 are uncommon in nodular lymphocyte-predominant Hodgkin's lymphoma.
  • Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) shows constitutive NF-kappaB activity in the malignant lymphocyte-predominant (LP) cells.
  • Constitutive NF-kappaB activity also plays a central pathogenetic role in classical Hodgkin's lymphoma (cHL), where inactivating mutations in the NFKBIA and TNFAIP3 genes, coding for the negative NF-kappaB regulators IkappaBalpha and A20, respectively, contribute to NF-kappaB activation.
  • To determine whether mutations in NFKBIA and TNFAIP3 are also involved in the pathogenesis of NLPHL these genes were sequenced from microdissected LP cells of 10 primary NLPHL.
  • [MeSH-minor] Cell Line, Tumor. DNA-Binding Proteins. Humans. Lymphoma, Follicular / genetics. Lymphoma, Follicular / metabolism. Lymphoma, Follicular / pathology. Mutagenesis, Insertional

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Nov 1;94(9):3129-34 [10556199.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1334-42 [19507254.001]
  • [Cites] Anal Biochem. 2000 Dec 1;287(1):25-31 [11078579.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):665-72 [12115499.001]
  • [Cites] Blood. 2003 Jan 15;101(2):706-10 [12393409.001]
  • [Cites] Nature. 2004 Aug 5;430(7000):694-9 [15258597.001]
  • [Cites] Cancer. 1985 Feb 15;55(4):683-90 [3881158.001]
  • [Cites] Am J Surg Pathol. 1988 Jan;12(1):9-21 [2827535.001]
  • [Cites] Leuk Lymphoma. 1993 Jan;9(1-2):1-25 [7682880.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6721-5 [8692885.001]
  • [Cites] J Clin Invest. 1997 Dec 15;100(12):2961-9 [9399941.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3063-70 [10340377.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2679-84 [16532038.001]
  • [Cites] Hum Pathol. 2006 Jun;37(6):675-83 [16733207.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3387-90 [17652621.001]
  • [Cites] EMBO J. 2008 May 7;27(9):1357-67 [18401342.001]
  • [Cites] J Exp Med. 2008 Sep 29;205(10):2251-68 [18794340.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] J Exp Med. 2009 May 11;206(5):981-9 [19380639.001]
  • [Cites] Nature. 2009 Jun 4;459(7247):712-6 [19412163.001]
  • [Cites] Nature. 2009 Jun 4;459(7247):717-21 [19412164.001]
  • [Cites] J Exp Med. 2000 Jan 17;191(2):395-402 [10637284.001]
  • (PMID = 19648161.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / I-kappa B Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / NF-kappa B; 0 / Nuclear Proteins; 139874-52-5 / NF-kappaB inhibitor alpha; EC 6.3.2.19 / TNFAIP3 protein, human
  • [Other-IDs] NLM/ PMC2805741
  •  go-up   go-down


39. Eum EA, Kim H, Kim YM, Woo SJ, Cho JH, Min YJ, Park JH: Anorectal and gastric peripheral T-cell lymphoma, unspecified in a non-AIDS patient. Korean J Intern Med; 2006 Dec;21(4):262-5
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anorectal and gastric peripheral T-cell lymphoma, unspecified in a non-AIDS patient.
  • Anorectum is a rare location for malignant lymphoma.
  • Involvement of is rare even for the lynphoma associated with acquired immune deficiency syndrome (AIDS), and AIDS has a relatively increased frequency of anorectal lymphoma.
  • Most lymphomas in AIDS patients are of a B-cell origin, and T-cell lymphoma of the gastrointestinal tract is extremely rare.
  • We report here on a case of anorectal and gastric peripheral T-cell lymphoma, unspecified (PTCLu) in a non-AIDS patient.
  • Sigmoidoscopy showed anal and rectal submucosal tumor.
  • He underwent excisional biopsy for the anal mass and the diagnosis was PTCLu.
  • There was no lymphoma involved in the bone marrow.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / diagnosis. Lymphoma, T-Cell, Peripheral / pathology. Rectal Neoplasms / pathology. Stomach Neoplasms / pathology


40. Agostinelli C, Piccaluga PP, Went P, Rossi M, Gazzola A, Righi S, Sista T, Campidelli C, Zinzani PL, Falini B, Pileri SA: Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies. J Clin Pathol; 2008 Nov;61(11):1160-7
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral T cell lymphoma, not otherwise specified: the stuff of genes, dreams and therapies.
  • This observation seems to pave the way for the use of innovative drugs such as tyrosine kinase and histone deacetylase inhibitors whose efficacy has been proven in PTCL primary cell cultures.
  • Gene expression profiling also allows better distinction of PTCL/NOS from angioimmunoblastic T cell lymphoma, the latter being characterised by follicular T helper lymphocyte derivation and CXCL13, PD1 and vascular endothelial growth factor expression.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol Histol. 1996 Oct;18(5):337-44 [8908304.001]
  • [Cites] Ann Oncol. 1997 Jun;8(6):583-92 [9261528.001]
  • [Cites] Cell Prolif. 1997 Jan;30(1):37-47 [9332493.001]
  • [Cites] Ann Oncol. 1997 Oct;8(10):973-8 [9402170.001]
  • [Cites] J Pathol. 1997 Dec;183(4):432-9 [9496260.001]
  • [Cites] J Biochem. 1998 May;123(5):767-76 [9562604.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):643-55 [9630171.001]
  • [Cites] J Biol Chem. 2004 Jun 4;279(23):24015-23 [15044484.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):174-85 [15211477.001]
  • [Cites] J Immunol. 2004 Jul 1;173(1):68-78 [15210760.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):289-303 [15233906.001]
  • [Cites] Int Immunol. 2004 Aug;16(8):1109-24 [15210650.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4971-82 [15297397.001]
  • [Cites] Leuk Res. 2004 Dec;28(12):1287-92 [15475070.001]
  • [Cites] Virchows Arch. 2004 Oct;445(4):334-43 [15480768.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):392-7 [3082212.001]
  • [Cites] J Immunol. 1986 Jun 15;136(12):4480-6 [3086432.001]
  • [Cites] Am J Pathol. 1987 May;127(2):279-87 [3555102.001]
  • [Cites] Br J Haematol. 1987 Sep;67(1):19-24 [3499172.001]
  • [Cites] Blood. 1988 Aug;72(2):413-21 [3261178.001]
  • [Cites] Blood. 1988 Sep;72(3):1000-6 [3046680.001]
  • [Cites] Lancet. 1988 Dec 17;2(8625):1394-9 [2904526.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):549-56 [2849301.001]
  • [Cites] Mod Pathol. 2007 Jun;20(6):632-7 [17431414.001]
  • [Cites] Blood. 2007 Jun 1;109(11):4952-63 [17284527.001]
  • [Cites] Expert Opin Investig Drugs. 2007 Jul;16(7):1111-20 [17594194.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1059-66 [17640856.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3321-9 [17577022.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2316-23 [17581918.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9945-53 [17942927.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3345-51 [17634410.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10703-10 [18006812.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):396-7 [18245132.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Oncogene. 2002 Jun 27;21(28):4462-70 [12080476.001]
  • [Cites] Int J Cancer. 2002 Oct 10;101(5):454-60 [12216074.001]
  • [Cites] J Clin Oncol. 2002 Sep 15;20(18):3891-7 [12228210.001]
  • [Cites] Oncogene. 2002 Nov 21;21(53):8178-85 [12444554.001]
  • [Cites] Ann Hematol. 2002 Nov;81(11):646-50 [12454703.001]
  • [Cites] Am J Clin Pathol. 1989 Feb;91(2):152-8 [2464922.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1093-9 [2161617.001]
  • [Cites] Hum Pathol. 1990 Nov;21(11):1117-25 [2227919.001]
  • [Cites] Cancer. 1991 May 15;67(10):2566-78 [1826629.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1259-67 [1739925.001]
  • [Cites] Cancer. 1992 May 15;69(10):2571-82 [1568182.001]
  • [Cites] Histopathology. 1993 Apr;22(4):303-10 [8514273.001]
  • [Cites] Int J Cancer. 2003 Jan 1;103(1):12-20 [12455048.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8696-704 [12483522.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):319-24 [12527929.001]
  • [Cites] Oncogene. 2003 Jan 23;22(3):343-50 [12545155.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25808-15 [12736251.001]
  • [Cites] Blood. 2003 Aug 1;102(3):1042-50 [12689942.001]
  • [Cites] Eur J Biochem. 2003 Aug;270(16):3408-21 [12899698.001]
  • [Cites] Am J Pathol. 2003 Sep;163(3):1033-43 [12937144.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33801-8 [12826661.001]
  • [Cites] Blood. 2003 Sep 15;102(6):2213-9 [12750155.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Oncogene. 2003 Oct 30;22(49):7762-73 [14586402.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):767-77 [14608905.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1513-22 [14657710.001]
  • [Cites] Am J Surg Pathol. 2004 Jan;28(1):54-61 [14707864.001]
  • [Cites] Nat Cell Biol. 2004 Feb;6(2):146-53 [14743220.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):405-10 [14676776.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):849-55 [9789607.001]
  • [Cites] Curr Hematol Rep. 2005 Jan;4(1):23-30 [15610656.001]
  • [Cites] Ann Oncol. 2005 Feb;16(2):206-14 [15668271.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):527-39 [15486044.001]
  • [Cites] Lancet Oncol. 2005 Jun;6(6):440 [15925824.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2254-63 [16270046.001]
  • [Cites] J Immunol. 2005 Dec 15;175(12):7837-47 [16339519.001]
  • [Cites] Mol Cancer Ther. 2005 Dec;4(12):1867-79 [16373702.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1560-70 [16288225.001]
  • [Cites] Am J Surg Pathol. 2006 Apr;30(4):490-4 [16625095.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4500-7 [16484591.001]
  • [Cites] Semin Oncol. 2006 Apr;33(2 Suppl 5):S44-52 [16720203.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2472-9 [16636342.001]
  • [Cites] Mod Pathol. 2006 Aug;19(8):1101-7 [16680156.001]
  • [Cites] Blood. 2006 Aug 15;108(4):1174-82 [16675713.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12(23):7174-9 [17145843.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4163-9 [16902151.001]
  • [Cites] Hematol Oncol. 2006 Dec;24(4):175-80 [16783841.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):117-21 [17325855.001]
  • [Cites] J Clin Invest. 2007 Mar;117(3):823-34 [17304354.001]
  • [Cites] Haematologica. 2007 Apr;92(4):566-7 [17488672.001]
  • [Cites] Am J Surg Pathol. 2000 Jan;24(1):117-22 [10632495.001]
  • [Cites] Virchows Arch. 2000 Apr;436(4):357-64 [10834539.001]
  • [Cites] Mod Pathol. 2000 Jul;13(7):766-72 [10912936.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5603-7 [11059746.001]
  • [Cites] Am J Surg Pathol. 2001 Mar;25(3):395-400 [11224611.001]
  • [Cites] Mod Pathol. 2001 Feb;14(2):105-10 [11235901.001]
  • [Cites] Histopathology. 2001 Mar;38(3):250-70 [11260307.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] J Biol Chem. 2001 Jan 26;276(4):2802-7 [11060313.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 1;128(1):1-6 [11454421.001]
  • [Cites] Blood. 2002 Jan 15;99(2):627-33 [11781247.001]
  • [Cites] Int J Hematol. 2001 Dec;74(4):442-6 [11794701.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):935-42 [14990650.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Blood. 2004 Apr 15;103(8):2920-4 [15070664.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1837-48 [15111330.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):909-16 [8101471.001]
  • [Cites] Blood. 1993 Aug 1;82(3):807-12 [7687895.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1460-6 [8123837.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Virchows Arch. 1994;425(1):25-32 [7921409.001]
  • [Cites] J Hematother. 1994 Spring;3(1):15-31 [7922004.001]
  • [Cites] Am J Clin Pathol. 1994 Oct;102(4):483-9 [7524302.001]
  • (PMID = 18755717.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 113
  • [Other-IDs] NLM/ PMC2582342
  •  go-up   go-down


41. Murphy D, Parker J, Zhou M, Fadlelmola FM, Steidl C, Karsan A, Gascoyne RD, Chen H, Banerjee D: Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B). Mol Cancer; 2010 Jan 26;9:14
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Constitutively overexpressed 21 kDa protein in Hodgkin lymphoma and aggressive non-Hodgkin lymphomas identified as cytochrome B5b (CYB5B).
  • BACKGROUND: We have previously reported a novel constitutively overexpressed 21 kDa protein in Hodgkin Lymphoma (HL) and aggressive Non-Hodgkin Lymphomas (NHL).

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 1999 Aug;84(8):683-9 [10457402.001]
  • [Cites] Curr Opin Hematol. 2009 Jul;16(4):292-8 [19509496.001]
  • [Cites] Horm Metab Res. 2005 Jan;37(1):10-4 [15702432.001]
  • [Cites] J Mol Biol. 2005 Jul 22;350(4):631-40 [15967459.001]
  • [Cites] J Clin Oncol. 2005 Jul 20;23(21):4669-78 [16034043.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16269-74 [16258060.001]
  • [Cites] Proteomics. 2006 Jan;6(2):605-13 [16419013.001]
  • [Cites] Hematol Oncol. 2007 Mar;25(1):21-9 [17048263.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 May;13(5):594-600 [17448919.001]
  • [Cites] J Cell Sci. 2007 May 15;120(Pt 10):1743-51 [17456552.001]
  • [Cites] J Clin Oncol. 2007 Jul 1;25(19):2764-9 [17515574.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Jun-Jul;105(1-5):16-36 [17583495.001]
  • [Cites] Transfus Apher Sci. 2007 Aug;37(1):49-56 [17716946.001]
  • [Cites] J Pathol. 2007 Dec;213(4):429-40 [17935142.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):831-6 [18085611.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):4323-31 [18056703.001]
  • [Cites] Mol Cancer. 2008;7:2 [18179710.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Jan;80(1):71-5 [11867265.001]
  • [Cites] J Cell Sci. 2002 Apr 15;115(Pt 8):1689-702 [11950887.001]
  • [Cites] Genome Biol. 2002;3(12):RESEARCH0068 [12537557.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] N Engl J Med. 2003 Jun 12;348(24):2386-95 [12802024.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Bone Marrow Transplant. 2003 Oct;32(7):673-9 [13130314.001]
  • [Cites] BMC Bioinformatics. 2004 Feb 9;5:13 [15040819.001]
  • [Cites] BMC Genomics. 2004 Mar 9;5(1):20 [15113400.001]
  • [Cites] Hum Mol Genet. 2004 Sep 1;13(17):1827-37 [15229187.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1984;45(3):289-99 [6146220.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Blood. 1989 Oct;74(5):1678-89 [2477085.001]
  • [Cites] Cell. 1992 Feb 7;68(3):421-7 [1310894.001]
  • [Cites] Haematologia (Budap). 1991;24(2):83-90 [1840056.001]
  • [Cites] Am J Clin Pathol. 1994 Sep;102(3):292-8 [8085551.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4207-12 [8633042.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3355-62 [9363866.001]
  • [Cites] J Biol Chem. 1998 Aug 14;273(33):20860-6 [9694832.001]
  • [Cites] Nucleic Acids Res. 1998 Nov 1;26(21):5007-8 [9776767.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):103-11 [10328771.001]
  • [Cites] Mol Cancer. 2008;7:12 [18218123.001]
  • [Cites] Leukemia. 2008 Aug;22(8):1587-94 [18449208.001]
  • [Cites] J Biol Chem. 2008 Oct 10;283(41):27504-13 [18667436.001]
  • [Cites] Oncologist. 2009 Apr;14(4):425-32 [19342476.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3326-34 [15284123.001]
  • (PMID = 20100355.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 9035-39-6 / Cytochromes b5
  • [Other-IDs] NLM/ PMC2829491
  •  go-up   go-down


42. Yang S, Evens AM, Prachand S, Singh AT, Bhalla S, David K, Gordon LI: Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata. Clin Cancer Res; 2010 Oct 1;16(19):4755-68
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial-mediated apoptosis in lymphoma cells by the diterpenoid lactone andrographolide, the active component of Andrographis paniculata.
  • EXPERIMENTAL DESIGN: We studied the Burkitt p53-mutated Ramos cell line, the mantle cell lymphoma (MCL) line Granta, the follicular lymphoma (FL) cell line HF-1, and the diffuse large B-cell lymphoma (DLBCL) cell line SUDHL4, as well as primary cells from patients with FL, DLBCL, and MCL.
  • CONCLUSIONS: Andrographolide caused ROS-dependent apoptosis in lymphoma cell lines and in primary tumor samples, which was enhanced by depletion of GSH and inhibited by NAC or the pan-caspase inhibitor Z-VAD-FMK.
  • Further studies of diterpenoid lactones in lymphoma are warranted.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Phytomedicine. 2000 Oct;7(5):351-64 [11081986.001]
  • [Cites] J Exp Ther Oncol. 2003 May-Jun;3(3):147-58 [14641821.001]
  • [Cites] J Clin Pharm Ther. 2004 Feb;29(1):37-45 [14748896.001]
  • [Cites] J Ethnopharmacol. 2004 Jun;92(2-3):291-5 [15138014.001]
  • [Cites] BMC Cancer. 2004 Jun 18;4:26 [15207007.001]
  • [Cites] Bioorg Med Chem Lett. 2004 Sep 20;14(18):4711-7 [15324893.001]
  • [Cites] J Immunol. 2004 Sep 15;173(6):4207-17 [15356172.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Biochem J. 1999 Feb 15;338 ( Pt 1):107-13 [9931305.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Jan;312(1):366-72 [15331658.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1265-73 [15388578.001]
  • [Cites] Mol Cell. 2005 Feb 18;17(4):525-35 [15721256.001]
  • [Cites] Br J Pharmacol. 2005 Mar;144(5):680-6 [15678086.001]
  • [Cites] In Vivo. 2005 May-Jun;19(3):551-7 [15875775.001]
  • [Cites] Planta Med. 2005 Dec;71(12):1106-11 [16395645.001]
  • [Cites] Blood. 2006 Mar 15;107(6):2501-6 [16291594.001]
  • [Cites] Biochem Pharmacol. 2006 Jul 14;72(2):132-44 [16740251.001]
  • [Cites] Pak J Pharm Sci. 2007 Jan;20(1):9-15 [17337421.001]
  • [Cites] Methods. 2008 Mar;44(3):229-34 [18314053.001]
  • [Cites] J Pharmacol Exp Ther. 2008 Apr;325(1):226-35 [18174384.001]
  • [Cites] J Asian Nat Prod Res. 2008 May-Jun;10(5-6):467-73 [18464090.001]
  • [Cites] J Nat Prod. 2008 May;71(5):852-5 [18357994.001]
  • [Cites] J Cell Sci. 2008 Jul 1;121(Pt 13):2186-96 [18544634.001]
  • [Cites] Mol Cancer Ther. 2008 Jul;7(7):2170-80 [18645026.001]
  • [Cites] Zhong Xi Yi Jie He Xue Bao. 2008 Dec;6(12):1238-45 [19063836.001]
  • [Cites] J Pharm Pharmacol. 2009 Jan;61(1):69-78 [19126299.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Feb 15;877(5-6):502-6 [19158000.001]
  • [Cites] Breast Cancer Res. 2008;10(6):R104 [19061505.001]
  • [Cites] Cancer Lett. 2009 Apr 18;276(2):180-8 [19097688.001]
  • [Cites] Drug Metab Lett. 2008 Dec;2(4):261-8 [19356103.001]
  • [Cites] Oncogene. 2009 Jul 23;28(29):2690-6 [19503098.001]
  • [Cites] Int J Toxicol. 2009 Jul-Aug;28(4):308-17 [19636073.001]
  • [Cites] Redox Rep. 2009;14(4):176-84 [19695125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):1232-9 [20610044.001]
  • [Cites] Phytother Res. 2000 Aug;14(5):333-8 [10925397.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • (PMID = 20798229.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K23 CA109613; United States / NCI NIH HHS / CA / K23 CA109613-A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Diterpenes; 0 / Reactive Oxygen Species; 410105JHGR / andrographolide
  • [Other-IDs] NLM/ NIHMS231241; NLM/ PMC2948634
  •  go-up   go-down


43. Rericha V, Kulich M, Rericha R, Shore DL, Sandler DP: Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners: a case-cohort study. Environ Health Perspect; 2006 Jun;114(6):818-22
Hazardous Substances Data Bank. URANIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of leukemia, lymphoma, and multiple myeloma in Czech uranium miners: a case-cohort study.
  • We investigated whether radon exposure is associated with increased incidence of leukemia, lymphoma, or multiple myeloma in this population.
  • DESIGN: We conducted a retrospective case-cohort study in 23,043 uranium miners and identified a total of 177 incident cases of leukemia, lymphoma, and myeloma.
  • Myeloid leukemia and Hodgkin lymphoma were also associated with radon, but RRs were not statistically significant.
  • There was no apparent association of radon with either non-Hodgkin lymphoma or multiple myeloma.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lifetime Data Anal. 2000 Mar;6(1):39-58 [10763560.001]
  • [Cites] Lancet. 2000 May 27;355(9218):1888 [10866451.001]
  • [Cites] Am J Epidemiol. 2000 Jul 1;152(1):91-5 [10901334.001]
  • [Cites] Radiat Res. 2000 Aug;154(2):178-86 [10931690.001]
  • [Cites] Am J Epidemiol. 2001 Feb 15;153(4):309-18 [11207146.001]
  • [Cites] Health Phys. 2001 Sep;81(3):272-88 [11513461.001]
  • [Cites] Leukemia. 2002 Jun;16(6):993-1007 [12040431.001]
  • [Cites] J Radiol Prot. 2002 Dec;22(4):389-406 [12546226.001]
  • [Cites] Health Phys. 2003 Jul;85(1):47-59 [12852471.001]
  • [Cites] IARC Sci Publ. 1987;(82):1-406 [3329634.001]
  • [Cites] Lancet. 1990 Apr 28;335(8696):1008-12 [1970069.001]
  • [Cites] Ann N Y Acad Sci. 1990;609:87-97; discussion 97-9 [2264660.001]
  • [Cites] Br J Radiol. 1991 Jul;64(763):608-24 [1651797.001]
  • [Cites] Am J Epidemiol. 1992 Nov 15;136(10):1232-40 [1476145.001]
  • [Cites] Radiat Res. 1993 May;134(2):224-33 [8488256.001]
  • [Cites] Br J Cancer. 1993 May;67(5):1090-7 [8494704.001]
  • [Cites] Epidemiology. 1994 Jan;5(1):48-56 [8117782.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • [Cites] J Natl Cancer Inst. 1995 Mar 1;87(5):378-84 [7853419.001]
  • [Cites] Environ Health Perspect. 1995 Mar;103 Suppl 2:55-7 [7614948.001]
  • [Cites] Int J Radiat Biol. 1995 Dec;68(6):669-78 [8551110.001]
  • [Cites] Environ Health Perspect. 1996 Dec;104 Suppl 6:1239-46 [9118899.001]
  • [Cites] J Natl Cancer Inst. 1998 Feb 18;90(4):294-300 [9486815.001]
  • [Cites] J Radiol Prot. 1999 Mar;19(1):3-26 [10321692.001]
  • [Cites] Environ Health Perspect. 2005 Jan;113(1):1-5 [15626639.001]
  • [Cites] BMJ. 2005 Jul 9;331(7508):77 [15987704.001]
  • [CommentIn] Environ Health Perspect. 2007 Apr;115(4):A184; author reply A184-5 [17450192.001]
  • (PMID = 16759978.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4OC371KSTK / Uranium
  • [Other-IDs] NLM/ PMC1480508
  •  go-up   go-down


44. Ortiz S, Lee W, Smith D, Forman SJ, Lee TD, Liu CP: Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells. Exp Biol Med (Maywood); 2010 Dec;235(12):1450-63
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.
  • Activation of T lymphoma cells expressing Syk, but not ZAP-70 tyrosine kinase, has been shown to negatively regulate cell activation and activation-induced cell death (AICD), perhaps due to differential induction of tyrosine phosphorylation modified proteins.
  • To better understand the role of these proteins and their associated molecules/pathways, we studied a previously described model of T lymphoma cells expressing either a kinase-activated chimeric Syk or ZAP-70 genetically linked to T-cell receptor (TCR) ζ chain (Z/Syk or Z/ZAP cells, respectively).
  • In summary, we identified proteins belonging to novel differentially activated pathways involved in TCR-mediated signaling, which may be targets for regulating activation and AICD of T lymphoma cells and for potential cancer therapy.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Top Microbiol Immunol. 2004;286:21-44 [15645709.001]
  • [Cites] J Biol Chem. 2004 Dec 31;279(53):55376-84 [15516342.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6233-7 [15879121.001]
  • [Cites] Expert Rev Proteomics. 2004 Dec;1(4):503-12 [15966845.001]
  • [Cites] Clin Chim Acta. 2005 Jul 24;357(2):123-39 [15970281.001]
  • [Cites] Mol Cell Proteomics. 2005 Oct;4(10):1487-502 [15979981.001]
  • [Cites] J Biol Chem. 2005 Nov 11;280(45):37471-80 [16154995.001]
  • [Cites] Curr Biol. 2006 Feb 7;16(3):R91-2 [16461271.001]
  • [Cites] J Proteome Res. 2006 Nov;5(11):2909-18 [17081042.001]
  • [Cites] Science. 2007 Jan 12;315(5809):201-5 [17218518.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1240-8 [17560012.001]
  • [Cites] J Proteome Res. 2008 Aug;7(8):3447-60 [18563927.001]
  • [Cites] J Biol Chem. 2008 Nov 21;283(47):32650-9 [18818202.001]
  • [Cites] Cell Res. 2009 Jan;19(1):58-70 [19050695.001]
  • [Cites] Immunol Today. 2000 Mar;21(3):148-54 [10689303.001]
  • [Cites] J Cell Biol. 2000 Aug 21;150(4):905-12 [10953014.001]
  • [Cites] Immunology. 2001 Aug;103(4):426-34 [11529932.001]
  • [Cites] Trends Biotechnol. 2001 Oct;19(10 Suppl):S40-8 [11780970.001]
  • [Cites] Annu Rev Biochem. 2001;70:437-73 [11395414.001]
  • [Cites] Curr Opin Mol Ther. 2002 Jun;4(3):210-5 [12139305.001]
  • [Cites] Semin Cancer Biol. 2003 Feb;13(1):29-40 [12507554.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):361-71 [14722044.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1472-82 [14734724.001]
  • [Cites] J Exp Med. 2004 Apr 5;199(7):981-91 [15067034.001]
  • [Cites] Anal Chem. 2004 May 15;76(10):2763-72 [15144186.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Blood. 2004 Aug 1;104(3):760-7 [15059847.001]
  • [Cites] Leukemia. 2010 Jan;24(1):229-32 [19776763.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Oct;52(1):9-17 [15363463.001]
  • [Cites] Immunol Lett. 1988 Oct;19(2):115-20 [2976733.001]
  • [Cites] J Biol Chem. 1994 Aug 12;269(32):20209-12 [8051109.001]
  • [Cites] Nature. 1995 Sep 7;377(6544):32-8 [7659156.001]
  • [Cites] Leukemia. 1996 Sep;10(9):1422-35 [8751458.001]
  • [Cites] Science. 1996 Dec 20;274(5295):2086-9 [8953040.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] J Mol Biol. 1998 Aug 21;281(3):523-37 [9698567.001]
  • [Cites] Immunity. 1998 Sep;9(3):305-13 [9768750.001]
  • [Cites] Int Immunol. 1998 Nov;10(11):1733-40 [9846702.001]
  • [Cites] Immunol Rev. 1998 Oct;165:167-80 [9850860.001]
  • [Cites] Exp Dermatol. 2005 Mar;14(3):188-93 [15740591.001]
  • (PMID = 21127342.001).
  • [ISSN] 1535-3699
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA107399-05; United States / NCI NIH HHS / CA / F31 CA117055; United States / NCI NIH HHS / CA / P50 CA107399-05; United States / NCI NIH HHS / CA / CA033572-27; United States / NCI NIH HHS / CA / P30 CA33572; United States / NCI NIH HHS / CA / P30 CA033572-27; United States / NCI NIH HHS / CA / P30 CA033572; United States / NCI NIH HHS / CA / F31 CA117055-03; United States / NCI NIH HHS / CA / P50 CA107399
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intracellular Signaling Peptides and Proteins; 0 / Receptors, Antigen, T-Cell; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Syk kinase; EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase
  • [Other-IDs] NLM/ NIHMS341439; NLM/ PMC3247199
  •  go-up   go-down


45. Nagamine CM, Jackson CN, Beck KA, Marini RP, Fox JG, Nambiar PR: Acute paraplegia in a young adult long-evans rat resulting from T-cell lymphoma. Contemp Top Lab Anim Sci; 2005 Nov;44(6):53-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute paraplegia in a young adult long-evans rat resulting from T-cell lymphoma.
  • We describe an unusual case of acute paraplegia in a young adult (7.5-month-old) Long-Evans rat that resulted from a spontaneous T-cell lymphoma.
  • At presentation, a neurologic exam revealed normal pelvic limb flexor reflexes, the absence of an anal reflex, and deep pain recognition.
  • Although the lymphoma did not invade the meninges of the spinal cord, its impingement on the central and peripheral nervous systems resulted in foci of Wallerian degeneration that contributed to the paraplegia.
  • This case report highlights the importance of having lymphoma and leukemia among the differential diagnoses in cases of acute paralysis in rodents.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16370582.001).
  • [ISSN] 1060-0558
  • [Journal-full-title] Contemporary topics in laboratory animal science
  • [ISO-abbreviation] Contemp Top Lab Anim Sci
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / T32-RR07036
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


46. Singh AT, Evens AM, Anderson RJ, Beckstead JA, Sankar N, Sassano A, Bhalla S, Yang S, Platanias LC, Forte TM, Ryan RO, Gordon LI: All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma. Br J Haematol; 2010 Jul;150(2):158-69
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell lymphoma.
  • Mantle cell lymphoma (MCL) is characterized by translocation t(11;14)(q13;q32), aggressive clinical behaviour, and poor patient outcomes following conventional chemotherapy.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Lymphoma, Mantle-Cell / pathology. Receptors, Retinoic Acid / drug effects. Tretinoin / pharmacology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1992 Dec 18;258(5090):1944-6 [1335166.001]
  • [Cites] Life Sci. 2003 Jan 3;72(7):831-6 [12479981.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):424-31 [12683869.001]
  • [Cites] Arch Pathol Lab Med. 2000 Oct;124(10):1457-62 [11035575.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]
  • [Cites] Blood. 2000 Jan 15;95(2):619-26 [10627471.001]
  • [Cites] J Biol Chem. 1997 Jul 18;272(29):17921-8 [9218416.001]
  • [Cites] Trends Mol Med. 2004 Oct;10(10):508-15 [15464451.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):367-73 [11234892.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Protein Expr Purif. 2003 Jan;27(1):98-103 [12509990.001]
  • [Cites] J Biol Chem. 2007 Oct 12;282(41):29987-97 [17656367.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(10):1747-53 [17574898.001]
  • [Cites] Blood. 2001 Jan 1;97(1):264-9 [11133770.001]
  • [Cites] J Cell Biochem. 2008 Aug 15;104(6):2185-92 [18425745.001]
  • [Cites] Ann Oncol. 1995 Jul;6(6):567-70 [8573535.001]
  • [Cites] Int J Pharm. 2007 Jul 18;339(1-2):246-50 [17412536.001]
  • [Cites] Cell Growth Differ. 1997 Oct;8(10):1071-82 [9342185.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):587-95 [15695403.001]
  • [Cites] J Cell Biochem. 2006 Feb 15;97(3):561-71 [16215989.001]
  • [Cites] Trends Cell Biol. 2009 Mar;19(3):89-98 [19168356.001]
  • [Cites] Haematologica. 2009 Nov;94(11):1555-62 [19880778.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):195-205 [16321849.001]
  • [Cites] Mol Cell Biol. 1994 Jan;14(1):360-72 [8264603.001]
  • [Cites] Breast Cancer Res. 2001;3(2):91-4 [11250752.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:101-6 [11905660.001]
  • [Cites] Leukemia. 2008 Nov;22(11):2097-105 [18685613.001]
  • [Cites] Carcinogenesis. 1997 May;18(5):943-8 [9163679.001]
  • [Cites] Oncologist. 1996;1(5):305-314 [10388008.001]
  • [Cites] Int J Oncol. 2008 Aug;33(2):397-404 [18636162.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2540-7 [10499631.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4315-21 [16123218.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 20;89(16):1191-8 [9274913.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):22013-8 [10419526.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):793-810 [17906642.001]
  • [Cites] Cell Growth Differ. 2000 Oct;11(10):517-26 [11063125.001]
  • [Cites] Int J Cancer. 2000 May 1;86(3):375-84 [10760826.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Pathol. 1996 Jul;179(3):238-42 [8774476.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):32544-51 [12805378.001]
  • [Cites] Leuk Res. 2003 Mar;27(3):259-66 [12537979.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Feb 6;379(2):466-9 [19114030.001]
  • [Cites] Expert Opin Drug Deliv. 2008 Mar;5(3):343-51 [18318655.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1265-73 [15388578.001]
  • [Cites] Med Princ Pract. 2003 Jul-Sep;12(3):164-9 [12766334.001]
  • [Cites] Annu Rev Nutr. 2004;24:201-21 [15189119.001]
  • (PMID = 20507312.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121192; United States / NHLBI NIH HHS / HL / R37 HL064159; United States / NCI NIH HHS / CA / R43 CA141904-01; United States / NHLBI NIH HHS / HL / R01 HL064159-12; United States / NCI NIH HHS / CA / 1R43CA141904; United States / NCI NIH HHS / CA / P30 CA060553; United States / NHLBI NIH HHS / HL / HL-64159; United States / NHLBI NIH HHS / HL / R01 HL064159; United States / NCI NIH HHS / CA / R43 CA141904; United States / NCI NIH HHS / CA / R01 CA121192-05; United States / NCI NIH HHS / CA / CA121192
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoates; 0 / Cell Cycle Proteins; 0 / Chromans; 0 / Guanine Nucleotide Exchange Factors; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RCC1 protein, human; 0 / Reactive Oxygen Species; 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 144092-31-9 / Ro 41-5253; 5688UTC01R / Tretinoin
  • [Other-IDs] NLM/ NIHMS212465; NLM/ PMC2907750
  •  go-up   go-down


47. Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM: An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer; 2009 Dec 03;8:115
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals.
  • The purpose of this study was to evaluate anti-lymphoma activity of MI-319 in WSU-FSCCL, a B-cell follicular lymphoma line.
  • In our systemic mouse model for FSCCL, MI-319 was tolerated well by the animals, displayed effectiveness against FSCCL-lymphoma cells in blood, brain and bone marrow, and achieved significant therapeutic impact (p < 0.0001) by conferring the treatment group a > 28% (%ILS, 14.4 days) increase in median survival days.
  • CONCLUSION: Overall, MI-319 probably has an anti-lymphoma potency equal to that of MI-219 and Nutlin-3.
  • It is a potent agent against FSCCL in vitro and in vivo and holds the promises to be developed further for the treatment of follicular lymphoma that retains wild-type p53.

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2001 Oct;1(1):68-76 [11900253.001]
  • [Cites] Cell Cycle. 2009 Jun 1;8(11):1711-9 [19411846.001]
  • [Cites] Science. 2004 Feb 6;303(5659):844-8 [14704432.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 Nov;52(2):103-16 [15501075.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Nucleic Acids Res. 1988 Feb 11;16(3):1215 [3344216.001]
  • [Cites] Blood. 1993 Jun 1;81(11):3034-42 [8499639.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Oct 1;70(1):62-7 [8221615.001]
  • [Cites] Cell. 1993 Nov 19;75(4):817-25 [8242752.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2412-21 [7919360.001]
  • [Cites] Cell. 1995 Jan 27;80(2):293-9 [7834749.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1305-14 [9607591.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Cell Mol Life Sci. 1999 Jan;55(1):96-107 [10065155.001]
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8199-207 [15548685.001]
  • [Cites] J Am Chem Soc. 2005 Jul 27;127(29):10130-1 [16028899.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):160-9 [16432175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1888-93 [16443686.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1582-9 [16575009.001]
  • [Cites] Blood. 2006 May 15;107(10):4122-9 [16439677.001]
  • [Cites] Blood. 2006 May 15;107(10):4109-14 [16439685.001]
  • [Cites] Blood. 2006 Aug 1;108(3):993-1000 [16543464.001]
  • [Cites] Cell. 2006 Dec 29;127(7):1323-34 [17182091.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):661-5 [17251932.001]
  • [Cites] Nature. 2007 Feb 8;445(7128):656-60 [17251933.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1019-28 [17364023.001]
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):706-14 [17470738.001]
  • [Cites] Cancer. 2007 May 15;109(10):2077-82 [17394190.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3380-7 [17545546.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1584-93 [17971485.001]
  • [Cites] J Leukoc Biol. 2008 Feb;83(2):434-7 [17998303.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-8 [18316739.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5318-24 [18765522.001]
  • [Cites] CA Cancer J Clin. 2008 Sep-Oct;58(5):305-17 [18755938.001]
  • [Cites] Adv Cancer Res. 2000;77:81-137 [10549356.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Oncogene. 2000 Jun 22;19(27):3095-100 [10871862.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):673-82 [11463391.001]
  • [Cites] Mol Cell. 2001 Mar;7(3):683-94 [11463392.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3827-34 [18682598.001]
  • [Cites] Cancer Biol Ther. 2008 Sep;7(9):1418-26 [18769131.001]
  • [Cites] Oncol Res. 2003;13(6-10):429-36 [12725534.001]
  • (PMID = 19958544.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / BC / BC0009140; United States / NCI NIH HHS / CA / P30 CA22453-20; United States / NCI NIH HHS / CA / R01CA109389
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / MI 319; 0 / Spiro Compounds; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / Mdm2 protein, mouse; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  • [Other-IDs] NLM/ PMC2794250
  •  go-up   go-down


48. Bertrand KA, Spiegelman D, Aster JC, Altshul LM, Korrick SA, Rodig SJ, Zhang SM, Kurth T, Laden F: Plasma organochlorine levels and risk of non-Hodgkin lymphoma in a cohort of men. Epidemiology; 2010 Mar;21(2):172-80
Hazardous Substances Data Bank. DDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma organochlorine levels and risk of non-Hodgkin lymphoma in a cohort of men.
  • BACKGROUND: Environmental exposure to polychlorinated biphenyls (PCBs) and p,p'-dichlorodiphenyldichloroethylene (p, p'-DDE) has been associated with the risk of non-Hodgkin lymphoma.
  • We measured concentrations of PCBs and p,p'-DDE in baseline blood samples from 205 men later diagnosed with non-Hodgkin lymphoma and 409 age- and race-matched controls.
  • We also evaluated these associations for major histologic subtypes of non-Hodgkin lymphoma.
  • RESULTS: The risk of non-Hodgkin lymphoma was positively associated with the sum of 51 PCB congeners assayed (SigmaPCB); the group of immunotoxic congeners; the individual congeners 118, 138, 153, and 180; and the sum of these 4 congeners.
  • There was no evidence of statistical heterogeneity in effects by histologic subtype of lymphoma; however, this analysis was underpowered.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):512-20 [15734980.001]
  • [Cites] Lancet. 1997 Jul 26;350(9073):240-4 [9242800.001]
  • [Cites] Pathology. 2005 Dec;37(6):409-19 [16373224.001]
  • [Cites] Crit Rev Toxicol. 2006 Oct;36(9):663-94 [17050081.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):373-6 [17337641.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5545-52 [17545638.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2767-75 [17722095.001]
  • [Cites] Occup Environ Med. 2008 Feb;65(2):132-40 [17699548.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Blood. 2009 Feb 26;113(9):1899-905 [19066394.001]
  • [Cites] Lancet Oncol. 2013 Apr;14(4):287-8 [23499544.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):193-7 [10698481.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):441-5 [10811571.001]
  • [Cites] J Expo Anal Environ Epidemiol. 2000 Nov-Dec;10(6 Pt 2):743-54 [11138666.001]
  • [Cites] Environ Health Perspect. 2001 Feb;109(2):173-8 [11266329.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):619-29 [11697490.001]
  • [Cites] Environ Health Perspect. 2002 Jun;110(6):595-600 [12055051.001]
  • [Cites] Sci Total Environ. 2002 May 6;290(1-3):181-98 [12083709.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] Am J Epidemiol. 2004 Mar 1;159(5):454-66 [14977641.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):532-7 [15066916.001]
  • [Cites] Environ Health Perspect. 2004 Jun;112(8):854-61 [15175172.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1665-76 [15466985.001]
  • [Cites] Am J Epidemiol. 1985 Jul;122(1):51-65 [4014201.001]
  • [Cites] Stat Med. 1989 May;8(5):551-61 [2657958.001]
  • [Cites] Arch Environ Contam Toxicol. 1989 Jul-Aug;18(4):495-500 [2505694.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5566s-5569s [1394175.001]
  • [Cites] Phys Med Biol. 1995 Sep;40(9):1475-85 [8532760.001]
  • [Cites] JAMA. 1996 May 1;275(17):1315-21 [8614116.001]
  • [Cites] Environ Health Perspect. 1997 Jan;105(1):13-4 [9074863.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11214-26 [16322272.001]
  • (PMID = 20087190.001).
  • [ISSN] 1531-5487
  • [Journal-full-title] Epidemiology (Cambridge, Mass.)
  • [ISO-abbreviation] Epidemiology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA097193-01; United States / NCI NIH HHS / CA / R01 CA098122; United States / NHLBI NIH HHS / HL / HL26490; United States / NHLBI NIH HHS / HL / HL34595; United States / NCI NIH HHS / CA / R01 CA097193-01; United States / NCI NIH HHS / CA / CA34944; United States / NCI NIH HHS / CA / R01 CA098122-04; United States / NHLBI NIH HHS / HL / R01 HL034595; United States / NCI NIH HHS / CA / CA098122; United States / NCI NIH HHS / CA / R01 CA034944-03; United States / NCI NIH HHS / CA / CA097193; United States / NHLBI NIH HHS / HL / R01 HL026490; United States / NHLBI NIH HHS / HL / R01 HL034595-07; United States / NCI NIH HHS / CA / R01 CA040360; United States / NIEHS NIH HHS / ES / T32 ES007155; United States / NHLBI NIH HHS / HL / R01 HL026490-03; United States / NCI NIH HHS / CA / R01 CA040360-14; United States / NCI NIH HHS / CA / R01 CA097193; United States / NCI NIH HHS / CA / CA40360; United States / NCI NIH HHS / CA / R01 CA034944; United States / NIEHS NIH HHS / ES / ES007155-21; United States / NIEHS NIH HHS / ES / T32 ES007155-21
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4M7FS82U08 / Dichlorodiphenyl Dichloroethylene; DFC2HB4I0K / Polychlorinated Biphenyls
  • [Other-IDs] NLM/ NIHMS237138; NLM/ PMC2957873
  •  go-up   go-down


49. Romesser PB, Perlman DH, Faller DV, Costello CE, McComb ME, Denis GV: Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma. Am J Pathol; 2009 Jul;175(1):25-35
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.
  • Previously, we showed that a subset of B cell lymphoma, diffuse large B cell lymphoma, may be characterized by two major, orthogonal axes of gene expression: one set of transcripts that is differentially expressed between resting and proliferating, nonmalignant cells (ie, a "proliferative signature") and another set that is expressed only in proliferating malignant cells (ie, a "cancer signature").
  • Here, we use a murine model of diffuse large B cell lymphoma to conduct unbiased two-dimensional gel electrophoresis and mass spectrometry-based comparative proteomic analyses of malignant proliferating B cells and tissue-matched, normal resting, or normal proliferating cells.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Biol. 2000 Oct;20(19):7146-59 [10982831.001]
  • [Cites] Nat Med. 2002 Jan;8(1):68-74 [11786909.001]
  • [Cites] Annu Rev Med. 2002;53:303-18 [11818476.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2598-606 [11909954.001]
  • [Cites] Cancer Lett. 2002 Sep 26;183(2):215-20 [12065097.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2572-7 [12239171.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6418-23 [12438227.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):49047-54 [12374812.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8862-70 [12483538.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(2):543-54 [12509453.001]
  • [Cites] Cancer Res. 2003 Jan 1;63(1):100-6 [12517784.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):198-207 [12634793.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):208-15 [12634794.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):226-32 [12634796.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1240-7 [12684390.001]
  • [Cites] Blood. 2004 Feb 15;103(4):1475-84 [14563639.001]
  • [Cites] Proteomics. 2004 Feb;4(2):442-7 [14760715.001]
  • [Cites] Proteomics. 2004 Mar;4(3):766-83 [14997498.001]
  • [Cites] J Struct Biol. 2004 Apr-May;146(1-2):44-57 [15037236.001]
  • [Cites] Mol Biol Cell. 2004 Apr;15(4):1862-70 [14767071.001]
  • [Cites] J Cell Biol. 2004 May 10;165(3):421-32 [15138294.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3371-5 [15150086.001]
  • [Cites] Mol Cell Biol. 2004 Jul;24(13):6000-10 [15199153.001]
  • [Cites] Oncogene. 1999 Jun 10;18(23):3501-10 [10376528.001]
  • [Cites] Curr Opin Cell Biol. 1999 Jun;11(3):363-71 [10395553.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8585-94 [15574765.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):291-2 [15659732.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):523-33 [15684406.001]
  • [Cites] Mol Cells. 2005 Apr 30;19(2):289-93 [15879716.001]
  • [Cites] Biochemistry. 2005 Jul 12;44(27):9417-29 [15996096.001]
  • [Cites] Mol Cell Biol. 2005 Oct;25(20):8874-86 [16199867.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Sep 3;321(4):1010-6 [15358129.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6315S-21S [15448024.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5283-92 [15454578.001]
  • [Cites] J Biol Chem. 1987 Aug 15;262(23):11389-97 [3301855.001]
  • [Cites] Blood. 1988 Apr;71(4):1033-8 [3258535.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3631-5 [7682714.001]
  • [Cites] Enzyme Protein. 1994-1995;48(1):37-44 [7787969.001]
  • [Cites] Exp Gerontol. 1995 Mar-Apr;30(2):99-124 [8591812.001]
  • [Cites] Exp Cell Res. 1996 Apr 10;224(1):128-35 [8612677.001]
  • [Cites] Anal Chem. 1996 Mar 1;68(5):850-8 [8779443.001]
  • [Cites] FEBS Lett. 1997 Feb 17;403(2):113-5 [9042948.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Mar 17;232(2):503-7 [9125210.001]
  • [Cites] Electrophoresis. 1998 May;19(6):893-900 [9638935.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1661-72 [10022854.001]
  • [Cites] J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27 [16204691.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1065-78 [16360036.001]
  • [Cites] J Proteome Res. 2006 Mar;5(3):502-11 [16512664.001]
  • [Cites] Cancer. 2006 May 15;106(10):2284-94 [16604531.001]
  • [Cites] J Cell Biol. 2006 May 8;173(3):395-404 [16651380.001]
  • [Cites] Curr Biol. 2006 Jun 20;16(12):R466-8 [16782004.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(16):6170-84 [16880527.001]
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):971-83 [16900146.001]
  • [Cites] Brief Bioinform. 2006 Jun;7(2):151-8 [16772265.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9705-13 [17018629.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6217s-6221s [17062704.001]
  • [Cites] Oncogene. 2006 Nov 30;25(56):7373-80 [16767159.001]
  • [Cites] Med Sci Monit. 2006 Dec;12(12):CR525-529 [17136009.001]
  • [Cites] J Biol Chem. 2007 Feb 16;282(7):4803-11 [17166848.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):169-75 [17591563.001]
  • [Cites] Recent Results Cancer Res. 2007;176:89-120 [17607919.001]
  • [Cites] Am J Pathol. 2007 Aug;171(2):375-85 [17600117.001]
  • [Cites] Drug Discov Today. 2007 Sep;12(17-18):700-8 [17826682.001]
  • [Cites] Leuk Lymphoma. 2008 Apr;49(4):663-76 [18398733.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1381-90 [18403594.001]
  • [Cites] Nature. 2008 Nov 6;456(7218):66-72 [18987736.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Curr Opin Immunol. 2000 Apr;12(2):219-25 [10712950.001]
  • (PMID = 19498000.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR010888-030019; United States / NCI NIH HHS / CA / CA128006; United States / NCRR NIH HHS / RR / RR010888-090116; United States / NCI NIH HHS / CA / CA075107-03; United States / NCRR NIH HHS / RR / P41 RR010888-136129; United States / NCI NIH HHS / CA / CA102889-02; United States / NCI NIH HHS / CA / R03 CA102889-01A1; United States / NCI NIH HHS / CA / R01 CA084193; United States / NCRR NIH HHS / RR / RR010888-136129; United States / NCI NIH HHS / CA / R29 CA075107-04; United States / NCRR NIH HHS / RR / RR010888-107084; United States / NCRR NIH HHS / RR / P41 RR010888-080116; United States / NHLBI NIH HHS / HV / N01-HV-28178; United States / NCI NIH HHS / CA / CA075107-04; United States / NCI NIH HHS / CA / R03 CA128006-01; United States / NCI NIH HHS / CA / R29 CA075107-03; United States / NCI NIH HHS / CA / R03 CA128006; United States / NHLBI NIH HHS / HL / N01HV28178; United States / NCRR NIH HHS / RR / RR010888-040020; United States / NCRR NIH HHS / RR / P41 RR010888-030019; United States / NCI NIH HHS / CA / R29 CA075107; United States / NCI NIH HHS / CA / R03 CA102889-02; United States / NCI NIH HHS / CA / R03 CA102889; United States / NCRR NIH HHS / RR / RR010888-125184; United States / NCI NIH HHS / CA / CA075107-05; United States / NCRR NIH HHS / RR / P41 RR010888-125184; United States / NCI NIH HHS / CA / R03 CA128006-02; United States / NCRR NIH HHS / RR / RR010888-05S10020; United States / NCRR NIH HHS / RR / P41 RR010888-05S10020; United States / NCRR NIH HHS / RR / RR010888-050020; United States / NCRR NIH HHS / RR / P41 RR010888-118005; United States / NCRR NIH HHS / RR / P41 RR010888-090116; United States / NCRR NIH HHS / RR / RR010888-118005; United States / NCI NIH HHS / CA / CA128006-01; United States / NCRR NIH HHS / RR / P41 RR010888-050020; United States / NCI NIH HHS / CA / CA128006-02; United States / NCRR NIH HHS / RR / P41 RR010888-040020; United States / NCRR NIH HHS / RR / P41 RR010888; United States / NCRR NIH HHS / RR / RR010888-080116; United States / NCRR NIH HHS / RR / P41 RR010888-107084; United States / NCI NIH HHS / CA / CA84193; United States / NCRR NIH HHS / RR / P41-RR10888; United States / NCRR NIH HHS / RR / S10-RR15942; United States / NCI NIH HHS / CA / R29 CA075107-05; United States / NCI NIH HHS / CA / CA102889-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC2708791
  •  go-up   go-down


50. Boyd RS, Jukes-Jones R, Walewska R, Brown D, Dyer MJ, Cain K: Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol Cell Proteomics; 2009 Jul;8(7):1501-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma.
  • We used shotgun proteomics to identify plasma membrane and lipid raft proteins purified from B cells obtained from mantle cell lymphoma (MCL) patients in leukemic phase.
  • Bioinformatics identified 111 transmembrane proteins, some of which were profiled in primary MCL cases, MCL-derived cell lines, and normal B cells using RT-PCR and Western blotting.
  • Significantly inhibitors of 5-LO activity (AA861) and 5-LO-activating protein (FLAP) (MK886, its activating enzyme) induced apoptosis in MCL cell lines and primary chronic lymphocytic leukemia cells, indicating an important role for the leukotriene biosynthetic pathway in MCL and other B cell malignancies.
  • [MeSH-major] Cell Membrane / chemistry. Lymphoma, Mantle-Cell / chemistry. Lymphoma, Mantle-Cell / physiopathology. Membrane Proteins / analysis. Neoplasm Proteins / analysis. Protein Array Analysis / methods. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Immunol. 2005 Jun;17(3):275-81 [15886117.001]
  • [Cites] Stem Cells. 2005 Oct;23(9):1367-77 [16210410.001]
  • [Cites] Leuk Res. 2006 Aug;30(8):911-3 [16563503.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):467-83 [10350444.001]
  • [Cites] J Biol Regul Homeost Agents. 2003 Oct-Dec;17(4):308-15 [15065759.001]
  • [Cites] Anal Chem. 2002 Oct 15;74(20):5383-92 [12403597.001]
  • [Cites] Pathol Int. 2001 Oct;51(10):747-61 [11881727.001]
  • [Cites] Nature. 2000 Apr 27;404(6781):999-1003 [10801129.001]
  • [Cites] Mol Cell Proteomics. 2005 Jul;4(7):924-35 [15849271.001]
  • [Cites] Nature. 2006 Apr 27;440(7088):1213-6 [16554753.001]
  • [Cites] Br J Haematol. 2002 Dec;119(4):905-15 [12472567.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):6941-8 [11120820.001]
  • [Cites] Curr Opin Immunol. 2004 Jun;16(3):367-73 [15134787.001]
  • [Cites] Int J Cancer. 2006 Nov 15;119(10):2247-54 [16921484.001]
  • [Cites] EMBO J. 2003 Jun 16;22(12):3015-26 [12805216.001]
  • [Cites] EMBO J. 1994 May 1;13(9):2124-30 [8187765.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1855-8 [12685844.001]
  • [Cites] Blood. 2005 May 1;105(9):3722-30 [15650054.001]
  • [Cites] Mol Cell Proteomics. 2002 Apr;1(4):304-13 [12096112.001]
  • [Cites] Curr Genomics. 2007 May;8(3):171-9 [18645603.001]
  • [Cites] Ann Hematol. 2006 Sep;85(9):597-603 [16830142.001]
  • [Cites] Nat Immunol. 2002 Aug;3(8):780-6 [12118249.001]
  • [Cites] Blood. 1993 Dec 1;82(11):3430-6 [8241510.001]
  • [Cites] FASEB J. 2003 Nov;17(14):1986-95 [14597668.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4181-90 [15899809.001]
  • [Cites] Leukemia. 2001 Sep;15(9):1388-97 [11516099.001]
  • [Cites] Nat Rev Immunol. 2002 Feb;2(2):96-105 [11910900.001]
  • [Cites] Br J Haematol. 2005 Aug;130(4):516-26 [16098065.001]
  • [Cites] J Pathol. 2005 Jun;206(2):123-34 [15880597.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):61-70 [14708026.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4554-61 [12036888.001]
  • [Cites] Blood. 2007 Feb 1;109(3):1193-201 [17003377.001]
  • [Cites] J Exp Med. 2000 May 1;191(9):1591-604 [10790433.001]
  • [Cites] BMC Immunol. 2009;10:2 [19134178.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7 [15075390.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5813-8 [12724530.001]
  • [Cites] Carcinogenesis. 1998 Jan;19(1):43-8 [9472691.001]
  • [Cites] Eur J Immunol. 1996 Dec;26(12):2964-71 [8977292.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):474-80 [11251968.001]
  • [Cites] Cancer Lett. 2007 Sep 8;254(2):236-43 [17467166.001]
  • [Cites] Mol Cells. 2007 Feb 28;23(1):57-63 [17464212.001]
  • [Cites] Trends Biochem Sci. 2007 Jul;32(7):332-41 [17576065.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2328-37 [16489038.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • [Cites] Blood. 2006 Jan 1;107(1):213-21 [16160011.001]
  • [Cites] Leuk Res. 2003 Sep;27(9):765-74 [12804633.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4398-405 [12154046.001]
  • [Cites] Br J Haematol. 1999 Aug;106(2):491-503 [10460611.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1605-12 [12886250.001]
  • [Cites] Electrophoresis. 2003 Jul;24(14):2376-85 [12874873.001]
  • [Cites] Nat Immunol. 2004 Aug;5(8):785-90 [15282562.001]
  • [Cites] Immunol Lett. 2005 Aug 15;100(1):94-7 [15975665.001]
  • [Cites] Bioessays. 2006 Aug;28(8):850-9 [16927317.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6409-14 [16155027.001]
  • [Cites] Mol Cell Biol. 1999 Mar;19(3):1720-30 [10022859.001]
  • [Cites] Mol Cell Proteomics. 2004 Oct;3(10):960-9 [15238602.001]
  • [Cites] Nat Immunol. 2006 Jun;7(6):625-33 [16648854.001]
  • [Cites] Anticancer Drugs. 2006 Aug;17(7):763-9 [16926626.001]
  • [Cites] Physiol Rev. 2003 Jul;83(3):731-801 [12843408.001]
  • [Cites] Pharmacol Ther. 2006 Dec;112(3):701-18 [16837050.001]
  • [Cites] Br J Haematol. 1998 May;101(2):302-10 [9609526.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4483-94 [8639814.001]
  • [Cites] Methods. 2005 Mar;35(3):303-14 [15722226.001]
  • [Cites] Nat Rev Immunol. 2002 Dec;2(12):945-56 [12461567.001]
  • [Cites] J Exp Med. 2004 Jan 5;199(1):59-68 [14707115.001]
  • (PMID = 19346216.001).
  • [ISSN] 1535-9484
  • [Journal-full-title] Molecular & cellular proteomics : MCP
  • [ISO-abbreviation] Mol. Cell Proteomics
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MRC/ MC/ U132670597
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; 0 / Lipoxygenase Inhibitors; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 1.13.11.34 / Arachidonate 5-Lipoxygenase; EC 2.7.11.13 / Protein Kinase C; EC 2.7.11.13 / Protein Kinase C beta
  • [Other-IDs] NLM/ PMC2709182
  •  go-up   go-down


51. Reddy LH, Adhikari JS, Dwarakanath BS, Sharma RK, Murthy RR: Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice. AAPS J; 2006;8(2):E254-62
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice.
  • The tumoricidal effects of etoposide incorporated into lipid nanoparticles after single-dose administration were investigated in Dalton's lymphoma ascites bearing mice.
  • [MeSH-major] Etoposide / pharmacokinetics. Etoposide / therapeutic use. Lymphoma / drug therapy. Nanostructures

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AAPS PharmSciTech. 2005;6(2):E158-66 [16353973.001]
  • [Cites] AAPS J. 2004;6(3):e23 [15760108.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1989 Mar;37(3):802-4 [2752497.001]
  • [Cites] Gan To Kagaku Ryoho. 1989 Aug;16(8 Pt 2):2743-7 [2782886.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):1033-40 [2808036.001]
  • [Cites] Gan To Kagaku Ryoho. 1991 May;18(6):959-63 [2029199.001]
  • [Cites] Gan To Kagaku Ryoho. 1991 Aug;18(11):2033-7 [1652233.001]
  • [Cites] J Neurooncol. 1993 Feb;15(2):133-9 [8509818.001]
  • [Cites] World J Surg. 1994 Jan-Feb;18(1):150-5 [8197772.001]
  • [Cites] Toxicol Lett. 2000 Jul 27;116(1-2):51-9 [10906422.001]
  • [Cites] Adv Drug Deliv Rev. 2001 Apr 25;47(2-3):165-96 [11311991.001]
  • [Cites] J Control Release. 2002 Apr 23;80(1-3):295-307 [11943406.001]
  • [Cites] Mutat Res. 1976 Dec;41(2-3):321-32 [796719.001]
  • [Cites] Indian J Med Res. 1985 Sep;82:266-8 [4077168.001]
  • [Cites] Anal Biochem. 1994 May 1;218(2):314-9 [8074286.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(3):211-6 [7781140.001]
  • [Cites] Int J Radiat Biol. 1995 Jun;67(6):677-85 [7608631.001]
  • [Cites] J Clin Oncol. 1996 Jun;14(6):1922-7 [8656261.001]
  • [Cites] Eur J Pharm Biopharm. 1998 Sep;46(2):145-51 [9795036.001]
  • [Cites] J Microencapsul. 1999 Mar-Apr;16(2):205-13 [10080114.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Mar 15;43(5):1125-33 [10192364.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):232-7 [3121165.001]
  • (PMID = 16796375.001).
  • [ISSN] 1550-7416
  • [Journal-full-title] The AAPS journal
  • [ISO-abbreviation] AAPS J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide
  • [Other-IDs] NLM/ PMC3231564
  •  go-up   go-down


52. Bai M, Katsanos KH, Economou M, Kamina S, Balli C, Briasoulis E, Kappas AM, Agnantis N, Tsianos EV: Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. Scand J Gastroenterol; 2006 Jul;41(7):866-9
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature.
  • Seven years after the adenocarcinoma diagnosis, the patient presented with severe continuous anal pain and diarrhea.
  • Sigmoidoscopy and subsequent biopsies from an ulcerated rectal area supported the diagnosis of Epstein-Barr virus-positive (EBV+) primary Hodgkin's lymphoma.
  • Only a few cases with primary gastrointestinal Hodgkin's lymphoma in Crohn's disease patients have so far been reported, including a variety of scenarios on the causal relationship including disease duration, presence of EBV, long-term immunosuppressive treatment and, recently, anti-TNFalpha administration.
  • [MeSH-minor] Adult. Humans. Immunosuppressive Agents. Male. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / virology

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16785203.001).
  • [ISSN] 0036-5521
  • [Journal-full-title] Scandinavian journal of gastroenterology
  • [ISO-abbreviation] Scand. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Number-of-references] 28
  •  go-up   go-down


53. Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG: A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults. Cancer Causes Control; 2010 Aug;21(8):1265-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case-control study of ultraviolet radiation exposure, vitamin D, and lymphoma risk in adults.
  • Recent research suggests that ultraviolet radiation exposure (UVRE), our major source of vitamin D, is associated with reduced lymphoma risk.
  • We conducted a clinic-based case-control study (140 lymphoma cases, 139 controls; 2002-2005, Rochester, NY) to evaluate UVRE and vitD insufficiency in relation to lymphoma risk.
  • We used multivariable logistic regression to estimate lymphoma risk in relation to past (5-10 years prior) UVRE and current vitD insufficiency (determined by serum 25(OH)D).
  • Possible differences in effect by lymphoma subtype were explored, but statistical power was limited.
  • We confirmed the previously reported decrease in lymphoma risk with past UVRE, specifically sunbathing (>once/week versus never); adjusted odds ratio (OR(adj)), = 0.28, 95% confidence interval (CI): 0.10-0.79.
  • Current vitD insufficiency was not associated with lymphoma risk (OR(adj) = 0.89, 95% CI: 0.47-1.72).
  • Therefore, while our data do not support an association with current vitD status, development of accurate methods for past vitD assessment to further investigate its role in the association between past UVRE and lymphoma risk is warranted.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Nutr. 2008 Apr;87(4):1102S-5S [18400742.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2059-61 [18984897.001]
  • [Cites] Blood. 2008 Dec 15;112(13):5150-60 [18796628.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):979-86 [19035445.001]
  • [Cites] Ann Epidemiol. 2009 Feb;19(2):73-8 [18329892.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1439-47 [19208842.001]
  • [Cites] Arch Intern Med. 2009 Mar 23;169(6):626-32 [19307527.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Jun;2(6):598-604 [19470790.001]
  • [Cites] Br J Nutr. 2010 Feb;103(4):581-4 [19781122.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2007 Jan;10(1):6-11 [17143048.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Nutr. 2001 Aug;86 Suppl 1:S97-103 [11520426.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):296-307 [12520530.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):247-54 [14619976.001]
  • [Cites] Am J Clin Nutr. 2004 Mar;79(3):362-71 [14985208.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):865-71 [15386383.001]
  • [Cites] Lancet. 1983 Mar 12;1(8324):545-8 [6131254.001]
  • [Cites] J Assoc Off Anal Chem. 1988 May-Jun;71(3):607-10 [3391970.001]
  • [Cites] Br J Cancer. 1991 Mar;63(3):463-5 [2003990.001]
  • [Cites] J Invest Dermatol. 1991 Oct;97(4):729-34 [1940446.001]
  • [Cites] Clin Chem. 1993 Mar;39(3):529-33 [8448871.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):668-72 [8398690.001]
  • [Cites] J Clin Endocrinol Metab. 1994 May;78(5):1202-7 [8175979.001]
  • [Cites] Acta Oncol. 1996;35(6):655-7 [8938209.001]
  • [Cites] Cancer Causes Control. 1997 Jul;8(4):605-9 [9242476.001]
  • [Cites] Cancer Causes Control. 1997 Jul;8(4):610-4 [9242477.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S [15585788.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S [15585789.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1981-2 [15599379.001]
  • [Cites] Arq Neuropsiquiatr. 2004 Dec;62(4):940-8 [15608949.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):161-3 [15687354.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3215-24 [15797954.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):713-8 [16556850.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):417-24 [16894287.001]
  • [Cites] Biomarkers. 2006 Jul-Aug;11(4):370-82 [16908443.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Am J Epidemiol. 2006 Dec 15;164(12):1222-32 [17005624.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):396-400 [17337644.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2445-51 [17311289.001]
  • [Cites] Med Hypotheses. 2007;69(1):182-5 [17197108.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):989-99 [17653830.001]
  • [Cites] Nutr Rev. 2007 Aug;65(8 Pt 2):S91-5 [17867379.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602 [17971526.001]
  • (PMID = 20373010.001).
  • [ISSN] 1573-7225
  • [Journal-full-title] Cancer causes & control : CCC
  • [ISO-abbreviation] Cancer Causes Control
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA130805-01A1; United States / NHLBI NIH HHS / HL / T32 HL007152-31; United States / NCI NIH HHS / CA / CA102216-05; United States / NCRR NIH HHS / RR / UL 1 RR024160; United States / NHLBI NIH HHS / HL / HL007152-33; United States / NCI NIH HHS / CA / K23 CA102216; United States / NHLBI NIH HHS / HL / HL007152-32; United States / NCI NIH HHS / CA / P50 CA130805-01A1; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NCI NIH HHS / CA / K23 CA102216-04; United States / NCI NIH HHS / CA / CA102216-02; United States / NIDDK NIH HHS / DK / R01 DK081843; United States / NHLBI NIH HHS / HL / HL007152-31; United States / NCI NIH HHS / CA / P50 CA130805-02; United States / NCI NIH HHS / CA / CA102216-03; United States / NCI NIH HHS / CA / K23 CA102216-03; United States / NIDDK NIH HHS / DK / R01 DK076876; United States / NCRR NIH HHS / RR / UL1 RR024160; United States / NCI NIH HHS / CA / P50 CA130805; United States / NHLBI NIH HHS / HL / T32 HL007152-33; United States / NCI NIH HHS / CA / CA102216-04; United States / NCRR NIH HHS / RR / UL1 RR024160-01; United States / NCI NIH HHS / CA / K23 CA102216-05; United States / NCI NIH HHS / CA / CA130805-02; United States / NCI NIH HHS / CA / K23 CA102216-02; United States / NHLBI NIH HHS / HL / T32 HL007152-32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Other-IDs] NLM/ NIHMS207788; NLM/ PMC2904408
  •  go-up   go-down


54. Dennison JB, Balakrishnan K, Gandhi V: Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol; 2009 Nov;147(3):297-307
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis.
  • In the current study, the efficacy of 8-Cl-Ado was evaluated using mantle cell lymphoma (MCL) cell lines: Granta 519, JeKo, Mino, and SP-53.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):271-7 [10656458.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):415-21 [18536582.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5474-9 [11454694.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):665-73 [11821446.001]
  • [Cites] J Pathol. 2003 Jan;199(1):90-7 [12474231.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):424-31 [12683869.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1740-5 [12735303.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7968-74 [14633728.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):883-93 [15329894.001]
  • [Cites] J Biol Chem. 2004 Sep 24;279(39):40405-11 [15265873.001]
  • [Cites] Cancer Res. 1989 Feb 15;49(4):915-9 [2563234.001]
  • [Cites] Anal Biochem. 1989 Aug 1;180(2):222-6 [2554751.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3030-7 [8674058.001]
  • [Cites] Biochem Pharmacol. 1997 Jan 24;53(2):141-8 [9037246.001]
  • [Cites] Clin Cancer Res. 1996 Apr;2(4):653-8 [9816215.001]
  • [Cites] Blood. 2005 Jun 1;105(11):4455-62 [15718423.001]
  • [Cites] Ann Oncol. 2005 Jul;16(7):1169-76 [15851403.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2513-9 [15972445.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7013-23 [16145068.001]
  • [Cites] J Cell Biochem. 2006 Jan 1;97(1):166-77 [16173047.001]
  • [Cites] Leuk Res. 2006 Nov;30(11):1377-84 [16624404.001]
  • [Cites] Cancer Res. 2007 Oct 15;67(20):9913-20 [17942923.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):749-58 [18375822.001]
  • [Cites] Blood. 2008 Jun 1;111(11):5350-8 [18292288.001]
  • [Cites] Mol Cancer. 2008;7:37 [18474106.001]
  • [Cites] Int J Cancer. 2008 Jul 15;123(2):476-83 [18452174.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2253-61 [10733493.001]
  • (PMID = 19709085.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA136411-01A15414; United States / NCI NIH HHS / CA / R01 CA085915; United States / NCI NIH HHS / CA / P50 CA136411-01A15414; United States / NCI NIH HHS / CA / R01 CA085915-09; United States / NCI NIH HHS / CA / CA 85915; United States / NCI NIH HHS / CA / CA085915-09; United States / NCI NIH HHS / CA / CA136411; United States / NCI NIH HHS / CA / P50 CA136411
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA, Neoplasm; 146-77-0 / 2-Chloroadenosine; 34408-14-5 / 8-chloroadenosine; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ NIHMS146585; NLM/ PMC2778754
  •  go-up   go-down


55. van de Wetering CI, Coleman MC, Spitz DR, Smith BJ, Knudson CM: Manganese superoxide dismutase gene dosage affects chromosomal instability and tumor onset in a mouse model of T cell lymphoma. Free Radic Biol Med; 2008 Apr 15;44(8):1677-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manganese superoxide dismutase gene dosage affects chromosomal instability and tumor onset in a mouse model of T cell lymphoma.
  • We examined the impact of MnSOD expression in the development of T cell lymphoma in mice expressing proapoptotic Bax.
  • The effects of MnSOD on apoptosis, cell cycle, chromosomal instability (CIN), and lymphoma development were determined.
  • The observed effects of MnSOD support a role for ROS in CIN and tumor formation in this mouse model of T cell lymphoma.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 1979 Apr;39(4):1141-9 [217531.001]
  • [Cites] Biochim Biophys Acta. 1989 Jan 19;994(1):30-6 [2462451.001]
  • [Cites] J Cell Physiol. 1989 Jun;139(3):592-8 [2738104.001]
  • [Cites] Anal Biochem. 1989 May 15;179(1):8-18 [2547324.001]
  • [Cites] Cell. 1991 Nov 29;67(5):879-88 [1835668.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):3113-7 [8464931.001]
  • [Cites] Cell. 1993 Oct 22;75(2):229-40 [8402909.001]
  • [Cites] Cell. 1993 Oct 22;75(2):241-51 [7503812.001]
  • [Cites] Neurology. 1994 Mar;44(3 Pt 1):533-6 [7908424.001]
  • [Cites] FEBS Lett. 1995 Jan 16;358(1):1-3 [7821417.001]
  • [Cites] EMBO J. 1996 Dec 16;15(24):6991-7001 [9003775.001]
  • [Cites] Science. 1997 Feb 14;275(5302):967-9 [9020077.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2991-7 [9531611.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3986-92 [9731512.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2671-8 [10194447.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):5017-22 [10519417.001]
  • [Cites] Drug Metab Rev. 2004 Oct;36(3-4):747-62 [15554245.001]
  • [Cites] Oncogene. 2005 Jan 6;24(1):77-89 [15543233.001]
  • [Cites] Oncogene. 2005 Jan 13;24(3):367-80 [15531919.001]
  • [Cites] Front Biosci. 2005;10:1881-96 [15769673.001]
  • [Cites] Biomed Pharmacother. 2005 May;59(4):143-8 [15862707.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6255-63 [16024627.001]
  • [Cites] Clin Cancer Res. 2006 Apr 15;12(8):2468-75 [16638854.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7615-20 [16885361.001]
  • [Cites] Antioxid Redox Signal. 2006 Jul-Aug;8(7-8):1295-305 [16910777.001]
  • [Cites] Exp Neurol. 2007 Mar;204(1):458-61 [17097638.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):659-65 [11212265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2278-83 [11226230.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3230-9 [11309271.001]
  • [Cites] Mutat Res. 2001 Jun 2;477(1-2):7-21 [11376682.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6082-8 [11507057.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2001 Sep;281(3):H1422-32 [11514315.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Jul;283(1):C148-54 [12055083.001]
  • [Cites] Cancer Cell. 2002 Apr;1(3):289-98 [12086865.001]
  • [Cites] Eur J Biochem. 2002 Nov;269(22):5440-50 [12423342.001]
  • [Cites] J Cell Biochem. 2003 Jan 1;88(1):128-37 [12461782.001]
  • [Cites] Mol Cancer Ther. 2003 Apr;2(4):361-9 [12700280.001]
  • [Cites] Cell Death Differ. 2003 Jun;10(6):740-8 [12761582.001]
  • [Cites] Nature. 2003 Jul 31;424(6948):561-5 [12891360.001]
  • [Cites] Aging Cell. 2003 Oct;2(5):277-85 [14570235.001]
  • [Cites] Physiol Genomics. 2003 Dec 16;16(1):29-37 [14679299.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):501-12 [15130277.001]
  • [Cites] Cell. 1985 Jul;41(3):899-906 [3924412.001]
  • (PMID = 18291119.001).
  • [ISSN] 0891-5849
  • [Journal-full-title] Free radical biology & medicine
  • [ISO-abbreviation] Free Radic. Biol. Med.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA104695-04; United States / NCI NIH HHS / CA / P30 CA086862-069012; United States / NCI NIH HHS / CA / P30 CA086862; United States / NCI NIH HHS / CA / R01-CA100045; United States / NCI NIH HHS / CA / R01 CA104695; United States / NCI NIH HHS / CA / F31 CA103362; United States / NCI NIH HHS / CA / CA103362-03S1; United States / NCI NIH HHS / CA / R01 CA100045; United States / NCI NIH HHS / CA / F31 CA103362-03S1; United States / NCI NIH HHS / CA / R01 CA104695-04; United States / NCI NIH HHS / CA / CA086862-069012; United States / NCI NIH HHS / CA / 5F31CA103362; United States / NCI NIH HHS / CA / R01 CA100045-04; United States / NCI NIH HHS / CA / P30-CA086862
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bax protein, mouse; 0 / Reactive Oxygen Species; 0 / bcl-2-Associated X Protein; EC 1.15.1.1 / Superoxide Dismutase
  • [Other-IDs] NLM/ NIHMS46598; NLM/ PMC2374742
  •  go-up   go-down


56. Qu Z, Goldenberg DM, Cardillo TM, Shi V, Hansen HJ, Chang CH: Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood; 2008 Feb 15;111(4):2211-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action.
  • Combination immunotherapy with anti-CD20 and anti-CD22 mAbs shows promising activity in non-Hodgkin lymphoma.
  • While none of the parental mAbs alone or mixed had notable antiproliferative activity against Burkitt lymphoma cells when not cross-linked, the bsAbs [eg, anti-CD20 IgG-anti-CD22 (scFv)(2)] were inhibitory without cross-linking and synergistic with B-cell antigen (BCR)-mediated inhibition.
  • Finally, the bsAbs inhibited Daudi lymphoma transplant growth, but showed a significant advantage over the parental anti-CD20 mAb only at the highest dose tested.

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Apoptosis. 2006 Jun;11(6):1003-12 [16763785.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):6841-6 [16636283.001]
  • [Cites] Mol Immunol. 2007 Feb;44(6):1331-41 [16814387.001]
  • [Cites] Expert Rev Anticancer Ther. 2006 Oct;6(10):1341-53 [17069520.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Sep 7;360(4):759-64 [17631277.001]
  • [Cites] Int Immunopharmacol. 2004 Aug;4(8):1117-24 [15222987.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5327-34 [15328168.001]
  • [Cites] Anal Biochem. 1984 Feb;136(2):451-7 [6372541.001]
  • [Cites] Cell Immunol. 1989 Jan;118(1):85-99 [2463099.001]
  • [Cites] Cancer Res. 1989 Aug 15;49(16):4568-77 [2663143.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1549-60 [10587346.001]
  • [Cites] J Exp Med. 2000 Apr 17;191(8):1443-8 [10770810.001]
  • [Cites] J Immunol. 2000 Aug 1;165(3):1220-7 [10903719.001]
  • [Cites] Mol Immunol. 2000 Dec;37(18):1123-30 [11451417.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2001;:221-40 [11722986.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2701-13 [12171904.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]
  • [Cites] J Immunol Methods. 2003 Aug;279(1-2):219-32 [12969563.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3982S-90S [14506197.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):822-9 [14566834.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2868-78 [15102696.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):19893-901 [14976189.001]
  • [Cites] J Immunol. 1992 Mar 1;148(5):1547-53 [1531669.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3236-40 [8475064.001]
  • [Cites] Eur J Immunol. 1993 Jun;23(6):1358-63 [7684686.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jul 15;90(14):6444-8 [8341653.001]
  • [Cites] Cancer Immunol Immunother. 1993 Oct;37(5):293-8 [7691407.001]
  • [Cites] Biotechnology (N Y). 1993 Nov;11(11):1271-7 [7764189.001]
  • [Cites] J Biol Chem. 1994 Jan 7;269(1):199-206 [8276795.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):538-45 [8112889.001]
  • [Cites] Structure. 1994 Dec 15;2(12):1217-26 [7704531.001]
  • [Cites] Ther Immunol. 1994 Jan;1(1):3-15 [7584477.001]
  • [Cites] Mol Immunol. 1995 Dec;32(17-18):1413-27 [8643111.001]
  • [Cites] Nat Biotechnol. 1997 Feb;15(2):159-63 [9035142.001]
  • [Cites] Biochem Soc Trans. 1997 May;25(2):705-8 [9191187.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):344-8 [9417086.001]
  • [Cites] FEBS Lett. 1999 Jul 2;454(1-2):90-4 [10413102.001]
  • [Cites] Endocr Relat Cancer. 2004 Dec;11(4):659-87 [15613445.001]
  • [Cites] Clin Exp Immunol. 2005 Mar;139(3):439-46 [15730389.001]
  • [Cites] Methods Mol Med. 2005;110:173-83 [15901935.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5044-51 [15955901.001]
  • [Cites] Curr Oncol Rep. 2005 Sep;7(5):364-71 [16091197.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6394-9 [16155025.001]
  • [Cites] J Immunol. 2006 Jan 15;176(2):873-9 [16393971.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3880-6 [16864854.001]
  • (PMID = 18025153.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R43 CA110297; United States / NCI NIH HHS / CA / CA110297
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / CD22 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 2; 0 / epratuzumab; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ PMC2234056
  •  go-up   go-down


57. Wu F, Wang P, Zhang J, Young LC, Lai R, Li L: Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Mol Cell Proteomics; 2010 Jul;9(7):1616-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
  • The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), found exclusively in a subset of ALK-positive anaplastic large cell lymphoma, promotes tumorigenesis by exerting its constitutively active tyrosine kinase activity.
  • Further validation of the TNF/Fas/TRAIL pathway was performed in ALK(+) anaplastic large cell lymphoma (ALCL) cell lines with knockdown of NPM-ALK using short interference RNA, resulting in the loss of the tyrosine phosphorylation of tumor necrosis factor receptor-associated protein 1 (TRAP1) and receptor-interacting protein 1, two crucial TNF signaling molecules.


58. Yan M, Shen J, Person MD, Kuang X, Lynn WS, Atlas D, Wong PK: Endoplasmic reticulum stress and unfolded protein response in Atm-deficient thymocytes and thymic lymphoma cells are attributable to oxidative stress. Neoplasia; 2008 Feb;10(2):160-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoplasmic reticulum stress and unfolded protein response in Atm-deficient thymocytes and thymic lymphoma cells are attributable to oxidative stress.
  • Using two-dimensional (2-D) gel electrophoresis and mass spectrometry (MS) analysis, we identified 22 differentially expressed proteins, including the ER stress marker glucose-regulated protein 78 (GRP78), in Atm-/- thymocytes and in Atm-/- thymic lymphoma cells relative to Atm+/+ thymocytes.
  • Cells of the ATL-1 line, which were derived from an Atm-/- mouse thymic lymphoma, were more sensitive to the ER stress inducer tunicamycin than were Atm+/+ thymic leukemia ASL-1 cells.

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9946-51 [12902539.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33741-9 [9837962.001]
  • [Cites] Carcinogenesis. 1999 Nov;20(11):2063-73 [10545407.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1561-70 [10749124.001]
  • [Cites] Free Radic Biol Med. 2000 May 1;28(9):1349-61 [10924854.001]
  • [Cites] Mol Cell. 2000 Dec;6(6):1355-64 [11163209.001]
  • [Cites] Physiol Rev. 2001 Apr;81(2):807-69 [11274345.001]
  • [Cites] FASEB J. 2001 May;15(7):1132-8 [11344081.001]
  • [Cites] Trends Biochem Sci. 2001 Aug;26(8):504-10 [11504627.001]
  • [Cites] J Biol Chem. 2001 Sep 7;276(36):33869-74 [11448953.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8322-30 [11719466.001]
  • [Cites] Carcinogenesis. 2002 Jan;23(1):123-30 [11756233.001]
  • [Cites] Cell. 2001 Dec 28;107(7):881-91 [11779464.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Nature. 2002 Jan 3;415(6867):92-6 [11780124.001]
  • [Cites] EMBO Rep. 2002 May;3(5):420-5 [11991946.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):99-111 [12110171.001]
  • [Cites] J Biol Chem. 2002 Sep 13;277(37):34287-94 [12097332.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5153-7 [12234978.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 10;300(2):327-32 [12504087.001]
  • [Cites] DNA Repair (Amst). 2002 Jan 22;1(1):3-25 [12509294.001]
  • [Cites] Nature. 2003 Jan 30;421(6922):499-506 [12556884.001]
  • [Cites] J Hepatol. 2003 May;38(5):605-14 [12713871.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):3095-102 [10082576.001]
  • [Cites] Cell Signal. 1999 Jan;11(1):1-14 [10206339.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):966-77 [15573118.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):136-45 [15589382.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9018-26 [15604267.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Mar;55(3):203-12 [15570424.001]
  • [Cites] Eur J Neurosci. 2005 Feb;21(3):637-46 [15733082.001]
  • [Cites] J Biol Chem. 2005 Oct 7;280(40):33917-25 [16107336.001]
  • [Cites] Brain Res. 2006 Jan 19;1069(1):198-206 [16386719.001]
  • [Cites] Curr Mol Med. 2006 Feb;6(1):45-54 [16472112.001]
  • [Cites] Free Radic Biol Med. 2006 Aug 15;41(4):640-8 [16863997.001]
  • [Cites] Cancer Biol Ther. 2006 Jul;5(7):721-2 [16880733.001]
  • [Cites] Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1391-418 [16986999.001]
  • [Cites] Biochem J. 2007 Jan 1;401(1):1-11 [17150040.001]
  • [Cites] J Proteome Res. 2007 Jan;6(1):273-86 [17203971.001]
  • [Cites] Science. 2007 May 25;316(5828):1160-6 [17525332.001]
  • [Cites] Oncogene. 2003 Nov 24;22(53):8608-18 [14634622.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):20108-17 [14978030.001]
  • [Cites] Antioxid Redox Signal. 2004 Jun;6(3):561-70 [15130282.001]
  • [Cites] J Neurochem. 2004 Jun;89(5):1241-51 [15147517.001]
  • [Cites] Nature. 2004 Oct 21;431(7011):997-1002 [15496926.001]
  • [Cites] Anal Biochem. 1992 May 15;203(1):173-9 [1524213.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4405-11 [8044789.001]
  • [Cites] Free Radic Biol Med. 1995 Apr;18(4):775-94 [7750801.001]
  • [Cites] Cell. 1996 Jul 12;86(1):159-71 [8689683.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13084-9 [8917548.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):117-30 [9516960.001]
  • [Cites] Nature. 1999 Jan 21;397(6716):271-4 [9930704.001]
  • (PMID = 18283338.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA123601-01; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / R03 CA123601; United States / NIEHS NIH HHS / ES / P30 ES007784; United States / NIEHS NIH HHS / ES / ES07784
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Eukaryotic Initiation Factor-2; 0 / HSP70 Heat-Shock Proteins; 0 / Heat-Shock Proteins; 0 / Membrane Proteins; 0 / Molecular Chaperones; 0 / Tumor Suppressor Proteins; 0 / glucose-regulated proteins; 0 / molecular chaperone GRP78; 11089-65-9 / Tunicamycin; BBX060AN9V / Hydrogen Peroxide; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.4.22.- / Caspase 3
  • [Other-IDs] NLM/ PMC2244691
  •  go-up   go-down


59. Miyamoto S, Liu R, Hung S, Wang X, Lam KS: Screening of a one bead-one compound combinatorial library for beta-actin identifies molecules active toward Ramos B-lymphoma cells. Anal Biochem; 2008 Mar 1;374(1):112-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of a one bead-one compound combinatorial library for beta-actin identifies molecules active toward Ramos B-lymphoma cells.
  • This method identified small molecule ligands that bound beta-actin present in cytoplasmic cell extracts of Ramos B-lymphoma cells.
  • These small molecule ligands were resynthesized in immobilized and soluble forms and tested for binding of beta-actin present in Ramos B-cell extracts and for activity against Ramos lymphoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2001 Dec;8(12):1167-82 [11755396.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3314-8 [8159745.001]
  • [Cites] J Am Chem Soc. 2002 Jul 3;124(26):7678-80 [12083920.001]
  • [Cites] J Am Chem Soc. 2003 May 21;125(20):6180-8 [12785850.001]
  • [Cites] Acc Chem Res. 2003 Jun;36(6):370-7 [12809522.001]
  • [Cites] Biochemistry. 1994 Dec 13;33(49):14825-33 [7993909.001]
  • [Cites] J Immunol Methods. 1995 Mar 27;180(2):219-23 [7714336.001]
  • [Cites] Int J Pept Protein Res. 1995 Jun;45(6):587-92 [7558590.001]
  • [Cites] Anticancer Drug Des. 1997 Apr;12(3):145-67 [9154108.001]
  • [Cites] Mol Divers. 1996 Oct;2(1-2):57-63 [9238634.001]
  • [Cites] Methods Mol Biol. 1998;87:7-12 [9523254.001]
  • [Cites] Nat Rev Cancer. 2004 Dec;4(12):948-55 [15573116.001]
  • [Cites] J Pept Res. 2005 Jan;65(1):130-8 [15686543.001]
  • [Cites] Mol Imaging. 2005 Oct-Dec;4(4):439-47 [16285906.001]
  • [Cites] Nat Chem Biol. 2006 Jul;2(7):381-9 [16767086.001]
  • [Cites] J Comb Chem. 2006 Jul-Aug;8(4):562-70 [16827569.001]
  • [Cites] Biomacromolecules. 2006 Nov;7(11):3037-46 [17096529.001]
  • [Cites] Biopolymers. 2006;84(6):595-604 [17041919.001]
  • [Cites] Bioconjug Chem. 2007 Jan-Feb;18(1):175-82 [17226971.001]
  • [Cites] Cell Signal. 2007 Aug;19(8):1621-32 [17553668.001]
  • [Cites] J Am Chem Soc. 2003 Nov 19;125(46):13995-4004 [14611236.001]
  • [Cites] Genes Dev. 2004 Apr 15;18(8):862-76 [15078817.001]
  • [Cites] J Am Chem Soc. 2004 May 12;126(18):5740-9 [15125667.001]
  • [Cites] J Am Chem Soc. 2004 Nov 3;126(43):14095-104 [15506774.001]
  • [Cites] Int J Pept Protein Res. 1991 Jun;37(6):487-93 [1917305.001]
  • [Cites] Nature. 1991 Nov 7;354(6348):82-4 [1944576.001]
  • [Cites] Nature. 1991 Nov 7;354(6348):84-6 [1719428.001]
  • [Cites] Comb Chem High Throughput Screen. 2002 Feb;5(1):83-91 [11860343.001]
  • (PMID = 18023409.001).
  • [ISSN] 0003-2697
  • [Journal-full-title] Analytical biochemistry
  • [ISO-abbreviation] Anal. Biochem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R33 CA099136-02; United States / NCI NIH HHS / CA / R33 CA099136-03; United States / NCI NIH HHS / CA / R01 CA098116; United States / NCI NIH HHS / CA / R33 CA099136-01; United States / NCI NIH HHS / CA / CA098116; United States / NCI NIH HHS / CA / CA099136; United States / NCI NIH HHS / CA / CA099136-02; United States / NCI NIH HHS / CA / R33 CA099136; United States / NCI NIH HHS / CA / CA099136-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antibodies, Monoclonal; 0 / Peptide Library
  • [Other-IDs] NLM/ NIHMS40764; NLM/ PMC2770001
  •  go-up   go-down


60. Wei J, Stebbins JL, Kitada S, Dash R, Placzek W, Rega MF, Wu B, Cellitti J, Zhai D, Yang L, Dahl R, Fisher PB, Reed JC, Pellecchia M: BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins. J Med Chem; 2010 May 27;53(10):4166-76
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins.
  • The compound also potently inhibits cell growth of human prostate cancer, lung cancer, and lymphoma cell lines with EC(50) values of 0.13, 0.56, and 0.049 microM, respectively, and shows little cytotoxicity against bax(-/-)bak(-/-) cells.

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • Hazardous Substances Data Bank. Gossypol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Med Chem. 2006 Oct 19;49(21):6139-42 [17034116.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14034-9 [16172403.001]
  • [Cites] J Med Chem. 2007 Feb 22;50(4):641-62 [17256834.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):970-81 [16909112.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):1046-53 [17363497.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6217-22 [17389404.001]
  • [Cites] Bioorg Chem. 2007 Aug;35(4):344-53 [17512966.001]
  • [Cites] Cell Death Differ. 2007 Sep;14(9):1711-3 [17572662.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5828-32 [17353899.001]
  • [Cites] Int J Cancer. 2007 Dec 1;121(11):2387-94 [17688235.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Mar;61(3):525-34 [17505826.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3211-9 [18202226.001]
  • [Cites] Cancer Lett. 2009 Jan 8;273(1):107-13 [18782651.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):904-13 [19372563.001]
  • [Cites] Cell Death Differ. 2009 Jul;16(7):1030-9 [19390557.001]
  • [Cites] J Med Chem. 2009 Jul 23;52(14):4511-23 [19555126.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2941-53 [10561374.001]
  • [Cites] J Biol Chem. 2000 Apr 14;275(15):11092-9 [10753914.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7124-9 [10860979.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7133-41 [11156422.001]
  • [Cites] Nat Cell Biol. 2001 Feb;3(2):173-82 [11175750.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Nat Rev Drug Discov. 2002 Feb;1(2):111-21 [12120092.001]
  • [Cites] Leukemia. 2003 Jan;17(1):211-9 [12529680.001]
  • [Cites] Biochem Pharmacol. 2003 Jul 1;66(1):93-103 [12818369.001]
  • [Cites] J Med Chem. 2003 Sep 25;46(20):4259-64 [13678404.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11376-80 [1454823.001]
  • [Cites] Chem Biol. 2004 Mar;11(3):389-95 [15123268.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8758-73 [14647471.001]
  • [Cites] J Mol Graph. 1994 Jun;12(2):98-105 [7918258.001]
  • [Cites] J Med Chem. 1995 Jun 23;38(13):2427-32 [7608907.001]
  • [Cites] Science. 1997 Feb 14;275(5302):983-6 [9020082.001]
  • [Cites] J Mol Biol. 1997 Apr 4;267(3):727-48 [9126849.001]
  • [Cites] Adv Pharmacol. 1997;41:501-32 [9204157.001]
  • [Cites] J Comput Aided Mol Des. 1997 Sep;11(5):425-45 [9385547.001]
  • [Cites] Prostate. 1998 Mar 1;34(4):275-82 [9496902.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1322-6 [9735050.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Cell. 1999 Jan 22;96(2):245-54 [9988219.001]
  • [Cites] Genes Dev. 1999 Aug 1;13(15):1899-911 [10444588.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):13-21 [15657349.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1059-64 [15647352.001]
  • [Cites] Nature. 2005 Jun 2;435(7042):677-81 [15902208.001]
  • [Cites] Cancer Cell. 2005 Jul;8(1):5-6 [16023593.001]
  • [Cites] J Pharm Biomed Anal. 2006 Nov 16;42(5):581-6 [16859853.001]
  • (PMID = 20443627.001).
  • [ISSN] 1520-4804
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA149668-01; United States / NCI NIH HHS / CA / CA113318; United States / NCI NIH HHS / CA / U19 CA113318; United States / NCI NIH HHS / CA / U19 CA113318-04; United States / NCI NIH HHS / CA / R01 CA127641; United States / NCI NIH HHS / CA / CA113318-04; United States / NCI NIH HHS / CA / R01 CA149668-01; United States / NCI NIH HHS / CA / R01 CA097318; United States / NCI NIH HHS / CA / R01 CA149668; United States / NCI NIH HHS / CA / CA149668
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-N5-(2-phenylpropyl)-N5'-(2-phenylpropyl)-2,2'-binaphthyl-5,5'-dicarboxamide; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / apogossypol; KAV15B369O / Gossypol
  • [Other-IDs] NLM/ NIHMS202533; NLM/ PMC2880850
  •  go-up   go-down


61. Kelly JL, Friedberg JW, Calvi LM, van Wijngaarden E, Fisher SG: Vitamin D and non-Hodgkin lymphoma risk in adults: a review. Cancer Invest; 2009 Nov;27(9):942-51
MedlinePlus Health Information. consumer health - Vitamin D Deficiency.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vitamin D and non-Hodgkin lymphoma risk in adults: a review.
  • Recent epidemiologic studies demonstrate a reduction in non-Hodgkin lymphoma (NHL) risk with increased sunlight exposure.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Vitamin D.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):161-3 [15687354.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):407-9 [15769998.001]
  • [Cites] Cancer Causes Control. 2005 Mar;16(2):83-95 [15868450.001]
  • [Cites] Curr Med Res Opin. 2005 Apr;21(4):579-86 [15899107.001]
  • [Cites] Mayo Clin Proc. 2005 Aug;80(8):1087-97 [16092591.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):7-12 [16046261.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):103-9 [16081283.001]
  • [Cites] Ann Oncol. 2006 Apr;17(4):713-8 [16556850.001]
  • [Cites] J Natl Cancer Inst. 2006 Apr 5;98(7):451-9 [16595781.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):417-24 [16894287.001]
  • [Cites] Cancer Causes Control. 2006 Oct;17(8):1045-52 [16933055.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2007 Jan;10(1):6-11 [17143048.001]
  • [Cites] Am J Epidemiol. 2006 Dec 15;164(12):1222-32 [17005624.001]
  • [Cites] Leuk Lymphoma. 2006 Dec;47(12):2477-87 [17169793.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2832-8 [17179460.001]
  • [Cites] Am J Epidemiol. 2007 Jan 15;165(2):126-33 [17071845.001]
  • [Cites] Am J Clin Nutr. 2007 Mar;85(3):649-50 [17344484.001]
  • [Cites] J Steroid Biochem Mol Biol. 2007 Mar;103(3-5):642-4 [17267210.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):392-5 [17337642.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):405-8 [17337643.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):396-400 [17337644.001]
  • [Cites] J Dairy Sci. 2000 Jun;83(6):1210-6 [10877385.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):379-82 [10975543.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):383-94 [10975544.001]
  • [Cites] Br J Nutr. 2001 Aug;86 Suppl 1:S37-53 [11520423.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1105-13 [11706071.001]
  • [Cites] J Dairy Sci. 2001 Dec;84(12):2813-20 [11814039.001]
  • [Cites] Am J Epidemiol. 2002 Sep 15;156(6):527-35 [12226000.001]
  • [Cites] Proc Nutr Soc. 2002 Aug;61(3):375-80 [12230797.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 4:147-52 [12401681.001]
  • [Cites] J Cell Biochem. 2003 Feb 1;88(2):296-307 [12520530.001]
  • [Cites] Semin Oncol. 2003 Apr;30(2 Suppl 4):3-9 [12728402.001]
  • [Cites] Recent Results Cancer Res. 2003;164:3-28 [12899511.001]
  • [Cites] Recent Results Cancer Res. 2003;164:371-7 [12899536.001]
  • [Cites] Mol Cell Biochem. 2003 Nov;253(1-2):247-54 [14619976.001]
  • [Cites] Photochem Photobiol Sci. 2003 Dec;2(12):1307-8; discussion 1308-10 [14717226.001]
  • [Cites] Am J Clin Nutr. 2004 Mar;79(3):362-71 [14985208.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):429-34 [15095310.001]
  • [Cites] Annu Rev Nutr. 2004;24:433-53 [15189127.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):449-52 [15225818.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):171-83 [15324700.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):401-4 [17337646.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2445-51 [17311289.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3479-88 [17185468.001]
  • [Cites] Int J Cancer. 2007;120 Suppl 12:1-39 [17405121.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] Am J Epidemiol. 2007 Jun 1;165(11):1255-64 [17327216.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1145-6 [17650449.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):989-99 [17653830.001]
  • [Cites] Nutr Rev. 2007 Aug;65(8 Pt 2):S77-9 [17867375.001]
  • [Cites] Nutr Rev. 2007 Aug;65(8 Pt 2):S91-5 [17867379.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602 [17971526.001]
  • [Cites] Am J Clin Nutr. 2008 Apr;87(4):1080S-6S [18400738.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1339-43 [18559548.001]
  • [Cites] Int J Epidemiol. 2008 Oct;37(5):1080-94 [18511490.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2059-61 [18984897.001]
  • [Cites] Int J Cancer. 2009 Feb 15;124(4):979-86 [19035445.001]
  • [Cites] Ann Epidemiol. 2009 Feb;19(2):73-8 [18329892.001]
  • [Cites] Proc Soc Exp Biol Med. 2000 Mar;223(3):230-3 [10719834.001]
  • [Cites] Eur J Cancer Prev. 2000 Feb;9(1):59-64 [10777011.001]
  • [Cites] CA Cancer J Clin. 2004 Sep-Oct;54(5):260-72 [15371284.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):865-71 [15386383.001]
  • [Cites] J Assoc Off Anal Chem. 1988 May-Jun;71(3):607-10 [3391970.001]
  • [Cites] Br J Cancer. 1991 Mar;63(3):463-5 [2003990.001]
  • [Cites] N Engl J Med. 1992 Apr 30;326(18):1178-81 [1313548.001]
  • [Cites] Cancer. 1992 Aug 15;70(4):840-9 [1643616.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5432s-5440s [1394149.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5453s-5455s [1394153.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5522s-5528s [1394167.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19 Suppl):5566s-5569s [1394175.001]
  • [Cites] Br J Cancer. 1993 Oct;68(4):668-72 [8398690.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1672-7 [8939849.001]
  • [Cites] Exp Biol Med (Maywood). 2004 Dec;229(11):1136-42 [15564440.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3463S-3471S [15570055.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):1-12 [15480663.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1673S-7S [15585787.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S [15585788.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S [15585789.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1710S-6S [15585792.001]
  • [Cites] Br J Cancer. 2004 Dec 13;91(12):1981-2 [15599379.001]
  • (PMID = 19832043.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA130805-01A1; United States / NHLBI NIH HHS / HL / T32 HL007152-31; United States / NHLBI NIH HHS / HL / HL007152-33; United States / NHLBI NIH HHS / HL / HL007152-32; United States / NCI NIH HHS / CA / P50 CA130805-01A1; United States / NHLBI NIH HHS / HL / T32 HL007152; United States / NIDDK NIH HHS / DK / R01 DK081843; United States / NHLBI NIH HHS / HL / HL007152-31; United States / NCI NIH HHS / CA / P50 CA130805-02; United States / NIDDK NIH HHS / DK / R01 DK076876; United States / NCRR NIH HHS / RR / UL1 RR024160; United States / NCI NIH HHS / CA / P50 CA130805; United States / NHLBI NIH HHS / HL / T32 HL007152-33; United States / NCRR NIH HHS / RR / UL1 RR024160-01; United States / NCI NIH HHS / CA / CA130805-02; United States / NHLBI NIH HHS / HL / T32 HL007152-32
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dihydroxycholecalciferols; 1406-16-2 / Vitamin D; P6YZ13C99Q / Calcifediol
  • [Number-of-references] 91
  • [Other-IDs] NLM/ NIHMS207770; NLM/ PMC2893413
  •  go-up   go-down


62. Watanabe M, Nakahata S, Hamasaki M, Saito Y, Kawano Y, Hidaka T, Yamashita K, Umeki K, Taki T, Taniwaki M, Okayama A, Morishita K: Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines. J Virol; 2010 Jul;84(14):6966-77
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of CDKN1A in adult T-cell leukemia/lymphoma despite overexpression of CDKN1A in human T-lymphotropic virus 1-infected cell lines.
  • Human T-lymphotropic virus 1 (HTLV-1) causes an aggressive malignancy of T lymphocytes called adult T-cell leukemia/lymphoma (ATLL), and expression of HTLV-1 Tax influences cell survival, proliferation, and genomic stability in the infected T lymphocytes.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Down-Regulation. Human T-lymphotropic virus 1 / metabolism. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / virology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Treat Options Oncol. 2001 Aug;2(4):291-300 [12057109.001]
  • [Cites] World J Gastroenterol. 2002 Jun;8(3):400-5 [12046058.001]
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1145-52 [12244301.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1153-60 [12244302.001]
  • [Cites] Nat Med. 2002 Oct;8(10):1136-44 [12244303.001]
  • [Cites] Mol Cell Biol. 2003 Jun;23(12):4056-65 [12773551.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6489-96 [14528273.001]
  • [Cites] Breast Cancer Res. 2003;5(6):R242-9 [14580260.001]
  • [Cites] Int J Cancer. 2004 Apr 20;109(4):559-67 [14991578.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3815-24 [15173090.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Jun;80(12):3618-22 [6304725.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Anal Biochem. 1995 Mar 20;226(1):161-6 [7785768.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4243-9 [7492783.001]
  • [Cites] Oncogene. 1999 Feb 11;18(6):1341-9 [10022816.001]
  • [Cites] Oncogene. 1999 Apr 15;18(15):2441-50 [10229195.001]
  • [Cites] Blood. 2005 Feb 1;105(3):1204-13 [15471956.001]
  • [Cites] J Infect Dis. 2005 Apr 1;191(7):1140-7 [15747250.001]
  • [Cites] Retrovirology. 2004;1:6 [15169570.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] J Virol. 2005 Nov;79(22):14069-78 [16254341.001]
  • [Cites] Retrovirology. 2005;2:64 [16242045.001]
  • [Cites] J Biol Chem. 2006 Mar 31;281(13):8927-38 [16436385.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3615-23 [18223691.001]
  • [Cites] Blood. 2008 Jul 15;112(2):383-93 [18467597.001]
  • [Cites] J Virol. 2008 Dec;82(23):11958-63 [18922876.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):2680-9 [19047050.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):262-5 [10667572.001]
  • [Cites] J Virol. 2000 Aug;74(16):7270-83 [10906181.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1695-700 [11080812.001]
  • [Cites] Nat Cell Biol. 2001 Mar;3(3):245-52 [11231573.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2291-6 [11895758.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12):3562-71 [12068005.001]
  • (PMID = 20444901.001).
  • [ISSN] 1098-5514
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Gene Products, tax; 0 / tax protein, Human T-lymphotrophic virus 1; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2898238
  •  go-up   go-down


63. Galietta A, Gunby RH, Redaelli S, Stano P, Carniti C, Bachi A, Tucker PW, Tartari CJ, Huang CJ, Colombo E, Pulford K, Puttini M, Piazza RG, Ruchatz H, Villa A, Donella-Deana A, Marin O, Perrotti D, Gambacorti-Passerini C: NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma. Blood; 2007 Oct 1;110(7):2600-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.
  • The oncogenic fusion tyrosine kinase nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) induces cellular transformation in anaplastic large-cell lymphomas (ALCLs) carrying the t(2;5) chromosomal translocation.
  • The interaction between NPM/ALK and PSF was dependent on an active ALK kinase domain and PSF was found to be tyrosine-phosphorylated in NPM/ALK-expressing cell lines and in primary ALK(+) ALCL samples.